Patients who are pregnant or breast-feeding are not eligible for this study as there is yet no available information regarding human fetal or teratogenic toxicities; negative pregnancy tests must be obtained in girls who are post-menarchal; patients of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study therapy; women of childbearing potential should be advised to use effective contraception for 4 months after the last dose of trametinib; breastfeeding women are excluded; female patients should not breastfeed during treatment with trametinib, and for 4 months following the last doseXx_NEWLINE_xXWomen of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug nivolumab; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab; women must not be breastfeeding; men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraceptionXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the studyXx_NEWLINE_xXWomen of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 6 months after the last dose of investigational drug; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropic [HCG]) within 72 hours prior to the start of nivolumab; women must not be breastfeeding; men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception; WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 6 months after the last dose of investigational product; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediatelyXx_NEWLINE_xXSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and until six months after completion of study therapyXx_NEWLINE_xXThe study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)Xx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; women of childbearing potential (WOCBP) receiving nivolumab will be instructed to adhere to contraception for a period of 5 months after the last dose of nivolumab; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of nivolumabXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXSexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participationXx_NEWLINE_xXPatients of childbearing potential unwilling to use contraceptive techniquesXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method both during and for 6 months after participation in this study; abstinence is an acceptable method of contraceptionXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method both during and for 3 months after participation in this study; abstinence is an acceptable method of contraceptionXx_NEWLINE_xXWomen with childbearing potential (WOCBP) who are negative for pregnancy test (urine or blood) and who agree to use effective contraceptive method; a woman of childbearing potential is defined of one who is biologically capable of becoming pregnant; reliable contraception should be used from trial screening and must be continued throughout the studyXx_NEWLINE_xXMales or females of reproductive potential may not participate unless they have agreed to use an effective double barrier contraceptive method for the entire duration of protocol therapy and for 3 months (males) and 1 month (females) after study drug discontinuationXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to practice abstinence or use an accepted and effective method of contraceptionXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective non-hormonal contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; corresponding procedures for men include castration, vasectomy and barrier contraceptive devices; however, if at any point a previously celibate patient chooses to become heterosexually active during the protocol therapy, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXFemales of childbearing potential must have negative serum or urine pregnancy test 7 days prior to registration and agree to use birth control throughout study and for 23 weeks after completion of protocol therapy; patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of “reproductive potential” if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, “effective contraception” also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXMen of reproductive potential must have agreed to use birth control throughout the study and for 31 weeks after completion of protocol therapy; in addition to routine contraceptive methods, “effective contraception” also includes heterosexual celibacy and surgery intended to prevent pregnancy (vasectomy); however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he is responsible for beginning contraceptive measuresXx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the studyXx_NEWLINE_xXPatients must not be pregnant or nursing; men and women of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse during the treatment period and for 31 weeks after the last nivolumab infusionXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXPatients must not be pregnant or nursing; females of child-bearing potential must have a negative serum pregnancy test within 7 days prior to registration; women/men of reproductive potential must have agreed to use an effective contraceptive method while on study and for at least 7 months after the last dose of study treatment; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures; hormonal contraception is not allowedXx_NEWLINE_xXWomen of childbearing potential (WOCBP) and males who are sexually active with WOCBP must use an accepted and effective method of contraception or abstain from sexual intercourse for at least one week prior to the start of treatment, and continue for 5 months after the last dose of protocol treatment for women of childbearing potential and 7 months after the last dose of protocol treatment for males who are sexually active with WOCBPXx_NEWLINE_xXMales who are sexually active with women of reproductive potential must have agreed to use birth control throughout the study and for 7 months after completion of protocol treatment; in addition to routine contraceptive methods, “effective contraception” also includes heterosexual celibacy and surgery intended to prevent pregnancy (vasectomy); if at any point a previously celibate patient chooses to become heterosexually active during or within 7 months after completion of protocol treatment, he is responsible for beginning effective contraceptive measuresXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the studyXx_NEWLINE_xXWomen of childbearing potential (WOCBP) and males who are sexually active with WOCBP must use an accepted and effective method of contraception or abstain from sexual intercourse for at least one week prior to the start of treatment, and continue for 5 months after the last dose of protocol treatment for women of childbearing potential and 7 months after the last dose of protocol treatment for males who are sexually active with WOCBPXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception also includes (but is not limited to) heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or vasectomy; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures\r\n* Women must agree to avoid breast-feeding and women of child-bearing potential (WOCBP) must agree to use highly effective contraception while receiving study drug and for a period of 31 weeks after the last dose of study drug; sexually-active men must agree to use a condom while receiving study drug and for 31 weeks after the last dose of study drug; vasectomized men must also agree to use a condom to avoid delivering drug in the seminal fluidXx_NEWLINE_xXSexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participationXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study and until 60 days from the last study treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative urine or serum pregnancy test within 28 day prior to registration; women/men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 120 days after the last dose of study medication; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or vasectomy; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures; patients must not be pregnant or nursingXx_NEWLINE_xXPatients who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXUnwillingness to use an effective contraceptive method for the duration of their study participation and for at least 1 month after treatment is completed if sexually active with reproductive potentialXx_NEWLINE_xXSexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for at least 3 months after treatment is completedXx_NEWLINE_xXFemale patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained; lactating females are not eligible unless they have agreed not to breastfeed their infants for the duration of protocol therapy; sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of protocol therapyXx_NEWLINE_xXSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participationXx_NEWLINE_xXMales and females of reproductive potential may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study and for 12 months post rituximab treatmentXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use accepted and effective methods of contraception, as described in the informed consent form (ICF), or to abstain from sexual intercourse for the duration of their participation in the study; women of childbearing potential should use adequate methods to avoid pregnancy for 23 weeks after the last dose of nivolumab; sexually active males should use adequate methods to avoid pregnancy for 31 weeks after the last dose of nivolumabXx_NEWLINE_xXSexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participationXx_NEWLINE_xXSexually active patients of reproductive potential who have not agreed to be abstinent or use 2 forms of effective contraception during treatment through 1 month off therapy are excludedXx_NEWLINE_xXSexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for 30 days after the last dose of chemotherapyXx_NEWLINE_xXNot pregnant and not nursing; for women of childbearing potential only, a negative serum pregnancy test must be obtained within 14 days prior to registration\r\n* Women of childbearing potential must use adequate contraception from study start to one month after the last dose of protocol therapy; adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence; men must practice complete abstinence or agree to use an adequate contraception method from study start to one month after the last dose of protocol therapyXx_NEWLINE_xXSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participationXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active should be willing and able to use medically acceptable forms of contraception during the trialtreatment on this study and for up to 180 days after completion of all treatment to prevent pregnancy or fathering a child.Xx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during treatment and for 180 days after the completion of all treatment; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic. Women who are breastfeeding are also excluded.Xx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential must have a negative urine or serum pregnancy test within 28 days prior to registration; women/men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 120 days after the last dose of study medication; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures; patients must not be pregnant or nursingXx_NEWLINE_xXSexually active patients of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of treatment and for 3 months after stopping treatmentXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatmentXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXPatients must not be pregnant or nursing; women of reproductive potential and men must have agreed to use an effective contraceptive method for the duration of study treatment and for 5 months (150 days) after the last dose of atezolizumab; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXSexually active women of childbearing potential and sexually active men must practice adequate contraception during therapy and for 12 months after protocol treatment completionXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method, while receiving study treatment and for 3 months after the last dose of JNJ-42756493 (erdafitinib); male subjects (with a partner of child-bearing potential) must use a condom with spermicide when sexually active and must not donate sperm from the first dose of study drug until 5 months after the last dose of study drugXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method, for the duration of study treatment and for 6 months after the last dose of vemurafenibXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment and for one week after the last dose of ensartinibXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatmentXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while receiving study treatment and for 3 months after the last dose of LY3023414Xx_NEWLINE_xXThis criteria apply ONLY to patients who will receive chemotherapy (all groups other than Group E1): \r\n* Female patients who are pregnant; a pregnancy test is required for female patients of childbearing potential\r\n* Lactating females who plan to breastfeed their infants\r\n* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation\r\n** Note for Group F: patients of childbearing potential should use effective birth control during treatment with sorafenib and for at least 2 weeks after stopping treatmentXx_NEWLINE_xXEvidence of non-childbearing status for women of childbearing potential (WOCBP). WOCBP must agree to use a highly effective contraceptive measure up to six weeks after treatment discontinuation. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last investigational medicinal product dose.Xx_NEWLINE_xXPregnant or breastfeeding women and fertile patients (men and women) who are not using an effective method of contraceptionXx_NEWLINE_xXWomen of child-bearing potential and men must agree to use adequate contraception prior to study entry, during the treatment portion of the study and for 4 months after completion of hetIL-15 administration.Xx_NEWLINE_xXUse an approved contraceptive method.Xx_NEWLINE_xXWomen of childbearing potential (including those who have had a tubal ligation) must have a documented negative pregnancy test within 14 days prior to planned initiation of taselisib; women of childbearing potential and men with partners of childbearing potential must be willing to use one highly effective form on nonhormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for 7 months after the last dose of study treatmentXx_NEWLINE_xXPatients must not be pregnant or nursing; women and men of reproductive potential must have agreed to use an effective contraceptive methodXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXIn case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatmentXx_NEWLINE_xXFertile men or women unwilling to use contraceptives during and for up to 12 months following treatmentXx_NEWLINE_xXAgree that during the trial, men will not father a child, and women cannot be or become pregnant. Participants must be of non-child bearing potential or agree to use one highly effective or combined contraceptive methods that result in a failure rate of <1% per year during the treatment period and at least through week 12 after last dose;Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) and men must agree to use effective contraceptive methods from Screening throughout the study treatment period and until at least 90 days after the last dose of either ipilimumab or IMO-2125, whichever is later.Xx_NEWLINE_xXIn sexually active patients (women of childbearing potential and males), willingness to use 2 effective methods of contraception, of which 1 must be a physical barrier method (condom, diaphragm, or cervical/vault cap) until 6 months after the last dose of FPA144. Other effective forms of contraception include:Xx_NEWLINE_xXMales who are sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug PRS 343 plus 90 days post-treatment completion.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use an effective contraception method during the study and for 30 days following the last dose of study drug; women of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy; men who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drugXx_NEWLINE_xXWomen of childbearing potential must be willing to abstain from heterosexual activity or use an effective method of contraception from the time of informed consent until 23 weeks after treatment discontinuationXx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving study drug and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational productXx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm;Xx_NEWLINE_xXFor women of childbearing potential: abstinent or use an effective form of contraceptive method for at least 3 months for cobimetinib and at least 5 months for atezolizumabXx_NEWLINE_xXPregnant or breastfeeding women will not be entered on this study; negative pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; the definition of adequate contraception will be based on the judgment of the principal investigator or designated associate; breastfeeding women are excludedXx_NEWLINE_xXFor men and women of child-producing potential, the use of effective contraceptive methods during the studyXx_NEWLINE_xXFor men and women of child bearing potential: agreement to remain abstinent or use protocol defined contraceptive measures during the treatment period and for at least 5 months after the last dose of atezolizumab/placebo, or for at least 6 months after the last dose of paclitaxelXx_NEWLINE_xXWomen of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatmentXx_NEWLINE_xXWomen of childbearing potential or fertile men and their partners must be willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 6 months following the last dose of MM-310.Xx_NEWLINE_xXFor women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least 6 months after the termination visit.Xx_NEWLINE_xXFor women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least 6 months after the termination visit.Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) must use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drugXx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential, ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraceptionXx_NEWLINE_xXWomen of child-bearing potential using hormonal contraception, unless an additional contraception method is also used according to the Mekinist® label. Additional exclusion criteria for Combination arm PDR001+EGF816Xx_NEWLINE_xXWomen of childbearing potential (not postmenopausal for at least one year or not surgically incapable of bearing children) must agree not to become pregnant for the duration of the study; both men and women must agree to use a barrier method of contraception for the duration of the study and until 8 weeks after the final doseXx_NEWLINE_xXWomen and men of reproductive potential must agree to use highly effective contraception when sexually active.Xx_NEWLINE_xXFemales of childbearing potential not using a medically acceptable means of contraception.Xx_NEWLINE_xXAgreement to remain abstinent or use adequate contraception, among women or men of childbearing potentialXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during treatment and for 3 months after stopping treatmentXx_NEWLINE_xXFor fertile men and women, agreement to use effective contraceptive methods duration of study participation and 90 days afterXx_NEWLINE_xXWomen of childbearing potential and men who are able to father a child, must agree to use an effective contraception method during study and for 12 months following study drug administrationXx_NEWLINE_xXMen or women of childbearing potential unwilling to employ adequate contraceptionXx_NEWLINE_xXWomen and men of child-producing potential must agree to use effective contraceptive methods during the study period (including post-treatment observation period)Xx_NEWLINE_xXMen whose sexual partners are women of childbearing potential not using a double method of contraception during the study and 3 months after the end of treatment; one of these methods must be a condomXx_NEWLINE_xXWomen of child-bearing potential (WOCBP) must agree to use an effective method(s) of contraception during treatment and during the post treatment follow-up periodXx_NEWLINE_xXFertile men and women unwilling to use contraceptive techniques during and for 12 months following treatmentXx_NEWLINE_xXWomen of childbearing potential and male participants must practice adequate contraceptionXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential and male participants must practice adequate contraceptionXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential and men with partners of childbearing potential, must be willing to use a highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the participants and/or partner, and to continue the use of contraception for the duration of study treatment and for at least 7 months after the last dose of study treatmentXx_NEWLINE_xXMen or women of childbearing potential who are unwilling to employ adequate contraceptionXx_NEWLINE_xXFertile men or women who are unwilling to use contraceptives during HCT and up to 12 months post-treatmentXx_NEWLINE_xXThe effects of nivolumab and ipilimumab on the developing human fetus are unknown; for this reason, women of childbearing potential (WOCBP) must agree to follow instructions for acceptable contraception from the time of signing consent, and for 23 weeks after their last dose of protocol-indicated treatment; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol who are not azoospermic who are sexually active with WOCBP must agree to follow instructions for acceptable contraception from the time of signing consent, and for 31 weeks after their last dose of protocol-indicated treatmentXx_NEWLINE_xXWomen of childbearing potential and men should remain abstinent or agree to use an effective form of contraception and to continue its use for the duration of study treatment and for a period of time after the last dose of study treatmentXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must agree to use appropriate method(s) of contraception; WOCBP should plan to use an adequate method to avoid pregnancy for 5 months (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drugXx_NEWLINE_xXMen who are sexually active with WOCBP must agree to use any contraceptive method with a failure rate of less than 1% per year; men who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product; women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraceptionXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must use appropriate method(s) of contraception for 23 weeks after the last dose of investigational drug; men who are sexually active with WOCBP must use any contraceptive method(s) with a failure rate of less than 1% per year for 31 weeks after the last dose of investigational drug; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXPHASE II INCLUSION CRITERIA: Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception for 23 weeks after the last dose of investigational drug; men who are sexually active with WOCBP must use any contraceptive method(s) with a failure rate of less than 1% per year for 31 weeks after the last dose of investigational drug; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXFor women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective form of hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner, and to continue the use of contraception for the duration of study treatment and for at least 6 months after the last dose of study treatment.Xx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab/placebo or 12 months after the last dose of chemotherapy.Xx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a non-hormonal contraceptive method with a failure rate of <1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab and within 3 months after the last dose of cobimetinibXx_NEWLINE_xXMen of reproductive potential who are sexually active with women of reproductive potential must use any contraceptive method with a failure rate of less than 1% per year; men who are receiving the study medications will be instructed to adhere to contraception for 31 weeks after the last dose of study drugs; men who are azoospermic do not require contraceptionXx_NEWLINE_xXPregnancy or lactation; women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participationXx_NEWLINE_xXFor men and women of child-bearing potential, willing to use adequate contraception (e.g., latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study.Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) or sexually active men must use appropriate method(s) of contraception.\r\n* Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception while on study treatment; WOCBP should use an adequate method to avoid pregnancy during study treatment and for 5 months (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug\r\n* Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception during study treatment and for a period of 7 months after the last dose of investigational product \r\n* Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile), as well as azoospermic men do not require contraceptionXx_NEWLINE_xXFor women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least 6 months after the termination visit.Xx_NEWLINE_xXSexually active females of childbearing potential and sexually active males with partners of reproductive potential: unwilling or unable to use appropriate contraception from screening until at least 6 months after last administration of study treatment.Xx_NEWLINE_xXWOCBP and men with female partners (WOCBP) that are not willing to use contraceptionXx_NEWLINE_xXPregnant or breast-feeding women are not eligible for this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Negative pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method beginning at the signing of the informed consent until at least 2 weeks after the last dose of the study drug. The definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate. Study drug may also potentially be secreted in milk and therefore breastfeeding women are excluded. Males (including those who have had vasectomies) with partners who can become pregnant will need to use birth control while on this study, as will their partner. Men are advised to use condoms during sexual intercourse while on study drug and continue to use adequate contraception for at least 2 weeks after the last dose of protocol therapy.Xx_NEWLINE_xXFor women who are not postmenopausal or surgically sterile: agreement to remain abstinent or use contraceptive methods that result in a failure rate of less than (<) 1 percent (%) per year during the treatment period and for at least 5 months after the last dose of atezolizumabXx_NEWLINE_xXWomen of childbearing potential and male participants must practice adequate contraceptionXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential should be willing and able to use medically acceptable forms of contraception during the trialXx_NEWLINE_xXFor men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:\r\n* With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 120 days after the last dose of guadecitabine; men must refrain from donating sperm during this same period\r\n* With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 30 days after the last dose of guadecitabine to avoid exposing the embryo\r\n* The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraceptionXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must agree to use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; WOCBP is defined as any woman or adolescent who has begun menstruation and is not post-menopausal; a post-menopausal woman is defined as a woman who is over the age of 45 and has not had a menstrual period for at least 12 monthsXx_NEWLINE_xXMen who are sexually active with WOCBP must agree to use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception)Xx_NEWLINE_xXFor women of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use of contraceptive methods that result in a failure rate of less than (<) 1 percent (%) per year during the treatment period and for at least 180 days after the last study treatmentXx_NEWLINE_xXThe potential effects of prexasertib (LY2606368) use during pregnancy and lactation are not known. Nonclinical studies of prexasertib on pregnancy and fetal development have not been performed; to minimize any potential risks, men and women with reproductive potential should use medically approved contraceptive precautions during treatment and for 3 months following the last dose of prexasertib; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 3 months after completion of prexasertib administration.Xx_NEWLINE_xXPregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXFor women of childbearing potential (defined as physiologically capable of becoming pregnant), agreement to use of highly effective contraception for at least 1 year following ACTR087 infusion. For men with partners of childbearing potential, agreement to use effective barrier contraception for at least 1 year following ACTR087 infusionXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen with child bearing potential and men with reproductive potential must be willing to practice acceptable methods of contraceptionXx_NEWLINE_xXSexually active patients and their partners agree to use an accepted method of contraception during the course of the study (Appendix C:Guidelines Regarding Women of Childbearing Potential).Xx_NEWLINE_xXPregnant or lactating women or women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXAgreement to remain abstinent or use adequate contraception, among women or men of childbearing potentialXx_NEWLINE_xXWomen who are pregnant or breast feeding and fertile patients (men and women) who are not using an effective method of contraception. All patients (men and women) must agree to use an effective method of contraception (if applicable) up to three months after treatment discontinuation.Xx_NEWLINE_xXMen or women of childbearing potential who are unwilling to employ adequate contraceptionXx_NEWLINE_xXPregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception during protocol treatment or for at least 6 months following treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate but is generally defined as a hormonal or barrier method of birth control, or abstinenceXx_NEWLINE_xXWomen of childbearing potential and male participants must practice adequate contraceptionXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential (not postmenopausal for at least one year or not surgically incapable of bearing children) must agree not to become pregnant for the duration of the study; both men and women must agree to use a barrier method of contraception for the duration of the study and until 10 weeks after the final dose of UC-961 (expected to be greater than 5 half-lives from pre-clinical data)Xx_NEWLINE_xXPatients who are pregnant or breast feeding will not be entered into the study; pregnancy tests must be obtained in females who are post-menarchal; post-menarchal females with HCG secreting tumors will be excluded; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of the studyXx_NEWLINE_xXSexually active patients of childbearing potential must be willing to use effective contraception during therapy and for at least 1 month after treatment is completedXx_NEWLINE_xXWomen of childbearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment with CC-486 or nab-paclitaxel; all men and women of childbearing potential must use effective methods of birth control throughout the study and for three months after completing treatmentXx_NEWLINE_xXPregnant or breast-feeding women; women of childbearing potential with either a positive or no pregnancy test at baseline; woman or men of childbearing potential not using a reliable and appropriate contraceptive method; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)Xx_NEWLINE_xXPregnant and/or breast-feeding women, or patients (men and women) of child-producing potential not willing to use medically acceptable forms of contraception while on study treatment and for at least 12 months after study treatment. Pregnancy testing is not necessary for women who have had a hysterectomy or have not had a menstrual period for at least 24 consecutive months.Xx_NEWLINE_xXPatients must not be pregnant or nursing because of the potentially harmful effects of these agents on a developing fetus; women/men of reproductive potential must have agreed to use an effective contraceptive methodXx_NEWLINE_xXWomen of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatmentXx_NEWLINE_xXPatients must not be pregnant or lactating as chemotherapy is thought to present substantial risk to the fetus/infant; women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment and negative serum or urine ?-hCG\r\npregnancy test at screening for patients of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential and sexually active males must commit to the use of effective contraception while on studyXx_NEWLINE_xXWomen of childbearing potential must agree to follow instructions for acceptable contraception from the time of signing consent, and for 23 weeks after their last dose of protocol-indicated treatment.Xx_NEWLINE_xXWomen of childbearing potential must be using an adequate method of contraception to avoid pregnancy during the study and for at least 4 months after the last dose of study drugs in such a manner that the risk of pregnancy is minimized. Men on study also must be using contraception. Women of childbearing potential (WOCBP) are women who have not been postmenopausal greater than 1 year or undergone a hysterectomy or bilateral oophorectomy.Xx_NEWLINE_xXPregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception; women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months; in addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth controlXx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of study treatment;Xx_NEWLINE_xXWomen who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug. Women of childbearing potential (WOCBP) and fertile men with WOCBP partner(s), not using and not willing to use a highly effective method of contraception.Xx_NEWLINE_xXA female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: \r\n* Not a woman of childbearing potential (WOCBP) OR\r\n* A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at 120 days after the last dose of study treatment. \r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participantXx_NEWLINE_xXWomen of childbearing potential (WOCBP) or male subjects with a partner who is WOCBP must agree to use contraception during the study, if sexually activeXx_NEWLINE_xXMen or women of childbearing potential who are unwilling to employ adequate contraceptionXx_NEWLINE_xXPatients must not be pregnant or breastfeeding; pregnancy tests must be obtained for all females of child-bearing potential within 10 days prior to enrollment; males or women of childbearing potential may not participate unless they have agreed to use an effective contraceptive method (defined as hormonal contraceptives, intrauterine devices, surgical contraceptives, or condoms)Xx_NEWLINE_xXUse of an effective means of contraception for women of childbearing potential and men with partners of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of study treatment and must be willing to use two methods of contraception one of them being a barrier method during the study and for 3 months after last study drug administrationXx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for the duration of treatment with study drug (s) plus 5 half-lives of study drug (s) plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment completion.Xx_NEWLINE_xXWomen who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception.Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) must use appropriate method(s) of contraception as stated for the timeline belowXx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per yearXx_NEWLINE_xXWomen of childbearing potential who are unable or unwilling to use an acceptable method of contraception.Xx_NEWLINE_xXIn females with childbearing potential, or men with partners of child bearing potential, willingness to use adequate contraception for a minimum duration of 155 days in females and 215 days in males, after last dose of nivolumabXx_NEWLINE_xXFor women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenibXx_NEWLINE_xXWomen of childbearing potential must have a negative urine or serum pregnancy test within 28 days prior to registration; women/men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 120 days after the last dose of study medication; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures; patients must not be pregnant or nursingXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must use appropriate method(s) of contraception. Appropriate methods of contraception are as follows. Women will be instructed to adhere to contraception for a period of 26 weeks after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 35 weeks after the last week of nivolumab/ipilimumab (nivo/ipi). Note: WOCBP is defined as any female who has experienced menarche and who has not yet undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented negative serum or urine test.Xx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 35 weeks after the last dose of investigational product. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception.Xx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method both during and for 3 months after participation in this study; abstinence is an acceptable method of contraception; those who become pregnant while on treatment with entinostat must discontinue immediately and consult their treating physicianXx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent or use at least two forms of effective contraceptive with a failure rate of < 1% per year during the treatment period and for at least 3 months after the last dose of cobimetinib and at least 5 months after the last dose of atezolizumab or pembrolizumabXx_NEWLINE_xXWomen of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of ?1% per year during the treatment period and for at least 5 months after the last dose of study treatmentXx_NEWLINE_xXWomen of child-bearing potential (WOCBP) and men able to father a child must agree to use highly effective contraception (any contraceptive method with a failure rate of less than 1 percent [%] per year) while on study drug and for 23 weeks (for women) or 31 weeks (for men) after the last dose of study drug\r\n* WOCBP must have a negative serum or urine pregnancy test within 24 hours of initiation of study drug\r\n* WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL to be defined as post-menopausal\r\n* WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; these durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days and men who are sexually active with WOCBP use contraception for 5 half-lives plus 90 days\r\n* Highly effective contraceptive measures include: stable use of oral contraceptives such as combined estrogen and progestogen and progestogen only hormonal contraception or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal ligation; vasectomy and sexual abstinence\r\n* Contraception is not required for men with documented vasectomy\r\n* Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation \r\n* Women must not be breastfeedingXx_NEWLINE_xXMen of reproductive potential who are sexually active with women of reproductive potential must use any contraceptive method with a failure rate of less than 1% per year; men who are receiving the study medications will be instructed to adhere to contraception for 31 weeks after the last dose of study drugs; men who are azoospermic do not require contraceptionXx_NEWLINE_xXWomen of childbearing potential or men who is unwilling to use an appropriate method of contraception during the study period and for 6 months after completing treatment with Debio 1347; oral or injectable contraceptive agents cannot be the sole method of contraceptionXx_NEWLINE_xXMen of reproductive potential who are sexually active with women of reproductive potential must use any contraceptive method with a failure rate of less than 1% per year; men who are receiving the study medications will be instructed to adhere to contraception for 31 weeks after the last dose of study drugs; men who are azoospermic do not require contraceptionXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to start of study drug. Sexually active subjects must be willing to use two medically accepted methods of contraception, one of them being a barrier method during the study and for 5 months (or 6 months for subjects on Combination Therapy cohort) after last study drug administration.Xx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment armXx_NEWLINE_xXNot a woman of childbearing potential (WOCBP) as defined in protocol ORXx_NEWLINE_xXWomen with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence.Xx_NEWLINE_xXWillingness to use contraception if childbearing potentialXx_NEWLINE_xXMen who are sexually active with women of childbearing potential must use contraceptive method with a failure rate of less than 1% per year. Contraception should be continued for a period of 90 days after the VTP procedure. The individual methods of contraception may be determined in consultationXx_NEWLINE_xXSexually active men and their sexual partners must use effective contraceptive methods from the time of subject informed consent and until at least 3 months after discontinuing study drugXx_NEWLINE_xXWomen of childbearing potential (WOCBP) and sexually active, non-sterile men must be willing to use acceptable method of contraception; WOCBP must agree to not get pregnant and sexually active, non-sterile men must agree not to impregnate a woman for at least 18 weeks after the last dose of nivolumabXx_NEWLINE_xXWomen who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug. Women of childbearing potential (WOCBP) and fertile men with WOCBP partner(s), not using and not willing to use a highly effective method of contraception.Xx_NEWLINE_xXWomen who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and azoospermic men do not require contraception.Xx_NEWLINE_xXFor women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least 6 months after the termination visit.Xx_NEWLINE_xXFemales of childbearing potential, and males, must be willing to use an effective method of contraceptionXx_NEWLINE_xXPregnant and lactating women will not be eligible; women of childbearing potential should have a negative urine pregnancy test prior to entering on the study and be willing to practice methods of contraception. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control.Xx_NEWLINE_xXMen able to father children who are sexually active with WOCBP must agree to use at least 2 methods of acceptable contraception from the time of signing consent and until 2 months after patient’s last dose of protocol-indicated treatment; men able to father children are defined as those who are not surgically sterile (i.e. patient has not had a vasectomy)Xx_NEWLINE_xXMen and women of childbearing potential must agree to use adequate contraception from the time of consent through 7 months after final nivolumab study treatmentXx_NEWLINE_xXWOCBP and men who are sexually active with WOCBP must use adequate contraception (e.g., hormonal or 2 barrier methods with a failure rate of less than 1% per year, or abstinence) prior to study entry and throughout study drug administration; WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational productXx_NEWLINE_xXWomen who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception)Xx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. The investigator shall review contraception methods and the time period that contraception must be followed. Men that are sexually active with WOCBP must follow instructions for birth control for a period of 90 days plus the time required for the investigational drug to undergo 5 half-lives (60 days).Xx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug.Xx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception.Xx_NEWLINE_xXFertile men or women unwilling to use contraceptive techniques during and for 12 months following treatmentXx_NEWLINE_xXNegative serum pregnancy test in women of childbearing potential within 7 days of first dose of treatment and patients of child-bearing potential must agree to use effective contraception during and after 90 days post dose. A woman of childbearing potential is defined as a premenopausal female capable of becoming pregnant. This includes women on oral, injectable or mechanical contraception; women who are single and women whose male sexual partners have been vasectomized or whose male sexual partners have received or are utilizing mechanical contraceptive devices.Xx_NEWLINE_xXWomen of childbearing potential and fertile men unwilling to use effective contraception during study until 4 months after conclusion of the treatment periodXx_NEWLINE_xXFor women of childbearing potential or male subjects: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year, during the treatment period and for at least 5 months after the last dose of treatmentXx_NEWLINE_xXMen unwilling to use appropriate contraceptive methods during the study and up to six months follow-up periodXx_NEWLINE_xXPregnancy or women of childbearing potential not willing/able to use contraception during protocol treatmentXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 5 months (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of\r\ninvestigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraceptionXx_NEWLINE_xXPregnant women, women of childbearing potential not willing to use contraception, men who are sexually active and not willing/able to use medically acceptable forms of contraception, and breast-feeding women not willing to stop breastfeeding during the studyXx_NEWLINE_xXWomen of child bearing potential (WOCBP) should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug(s); Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; Women who are not of childbearing potential as well as azoospermic men do not require contraceptionXx_NEWLINE_xXPersons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 12 weeks after study drug is stopped; prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancyXx_NEWLINE_xXPregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control.Xx_NEWLINE_xXMen and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participationXx_NEWLINE_xXFertile men and women unwilling to use contraceptives during and for 12 months post-transplantXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 5 months (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drugXx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product; women who are not of childbearing potential (i.e. who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraceptionXx_NEWLINE_xXAll patients (men & women) of childbearing potential should use a method of birth control that is effective for them throughout their participation in this study. Women of childbearing potential should use an adequate contraceptive method to avoid pregnancy for 5 months (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours before the start of nivolumab; and must not be breastfeeding. Men who are sexually active with women of childbearing potential must use a contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab will be instructed to use contraception for 7 months after the last dose of nivolumab. Women who are not of childbearing potential (i.e. are postmenopausal or surgically sterile) & azoospermic men do not require contraceptionXx_NEWLINE_xXAll patients (men & women) of childbearing potential should use method of birth control that is effective for them throughout their participation in this study. Women of childbearing potential should use an adequate contraceptive method to avoid pregnancy for 5 months (30 days plus the time required for nivolumab to undergo five half-lives) after last dose of investigational drug; must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours before the start of nivolumab; and must not be breastfeeding. Men who are sexually active with women of childbearing potential must use a contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab will be instructed to use contraception for 7 months after the last dose of nivolumab. Women who are not of childbearing potential (i.e., are postmenopausal or surgically sterile) and azoospermic men do not require contraceptionXx_NEWLINE_xXPregnant or nursing patients due to risk of fetal or nursing infant harm. Women/men of reproductive potential who do not agree to use an effective contraceptive method while on study and for at least 6 months after study treatmentXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 5 months (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drugXx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product; women who are not of childbearing potential, i.e., who are postmenopausal or surgically sterile as well as azoospermic men do not require contraceptionXx_NEWLINE_xXWomen of childbearing potential (defined as all women physiologically capable of becoming pregnant) must agree to both of the following:\r\n* Use highly effective methods of contraception for at least 6 months after the last dose of huJCAR014, and\r\n* Have a negative serum pregnancy test performed within 28 days before starting lymphodepleting chemotherapyXx_NEWLINE_xXWomen of childbearing potential must use method(s) of contraception; the individual methods of contraception should be determined in consultation with the treating physician or investigatorXx_NEWLINE_xXMen who are sexually active with women of childbearing potential must use any contraceptive method with a failure rate of less than 1% per yearXx_NEWLINE_xXPregnant or breast-feeding patients; men and women of reproductive potential may not participate in this study unless they have agreed to use an effective contraceptive method while in this studyXx_NEWLINE_xXWomen must not be pregnant or breastfeeding; all women of childbearing potential must have a blood test within 72 hours to rule out pregnancy; women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception; women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for 26 weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimized; sexually mature females who have not undergone a hysterectomy or who have not been postmenopausal naturally for at least 24 consecutive months (i.e., who have had menses at some time in the preceding 24 consecutive months) are considered to be of childbearing potential; women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g., vasectomy) should be considered to be of childbearing potentialXx_NEWLINE_xXIn case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatmentXx_NEWLINE_xXPregnant or lactating women; women and men of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finishedXx_NEWLINE_xXWomen with childbearing potential and partners must both use effective contraception during the study and for 3 months after the last doseXx_NEWLINE_xXNegative serum or urine pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only\r\n* Note: persons of child-bearing potential (POCBP) must use appropriate method(s) of contraception; POCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; men who are sexually active with POCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with POCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; persons who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception; should a person become pregnant or suspect being pregnant while participating in this study, the person should inform the treating physician immediatelyXx_NEWLINE_xXPregnant or lactating women; women and men of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finishedXx_NEWLINE_xXAny woman of childbearing potential, unless she:Xx_NEWLINE_xXSexually active women of child-bearing potential must be willing to use effective contraception through month 7 of the studyXx_NEWLINE_xXFor women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception; for men: agreement to use a barrier method of contraception during the treatment periodXx_NEWLINE_xXPatients must be willing to use contraception if they have childbearing potentialXx_NEWLINE_xXPregnancy, or unwillingness to use contraception if they have childbearing potentialXx_NEWLINE_xXAge and reproductive status:\r\n* Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 consecutive months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL\r\n* WOCBP must use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug\r\n* Women of childbearing potential must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to registration\r\n* Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year\r\n* Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product\r\n* Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile and azoospermic men are not required to use contraceptionXx_NEWLINE_xXWomen of childbearing potential or fertile men unwilling to use effective contraception during study until conclusion of 4-week post-treatment evaluation period.Xx_NEWLINE_xXAll men and women of childbearing potential must use acceptable methods of birth control throughout the study as described below:\r\n* Females of childbearing potential: Recommendation is for at least one highly effective contraceptive methods during the study and must agree to continue using such precautions for 180 days after the last dose of investigational product\r\n* Non-sterilized males: Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use male condom plus spermicide from screening through 180 days after the last dose of investigational productXx_NEWLINE_xXAny of the following:\r\n* Pregnant women or women of reproductive ability who are unwilling to use effective contraception\r\n* Nursing women\r\n* Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatmentXx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraceptionXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception beginning at the signing of the consent until at least 4 weeks after the last dose of study drugXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenicXx_NEWLINE_xXMen receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational productXx_NEWLINE_xXWomen of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 23 weeks) after the last dose of investigational drug nivolumab; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab; women must not be breastfeeding; men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraceptionXx_NEWLINE_xXMen and women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study, and for women at least 23 weeks after the last dose of investigational product and for men at least 31 weeks after the last dose of investigational product in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXWomen of childbearing potential and male participants must practice adequate contraceptionXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXFemales of child-bearing potential willing to use adequate contraceptive measures from the time of screening until 6 months after trial discontinuation, who are not or will not be breast feeding, and agree to have pregnancy tests prior to the start of dosing and at regular visits during the trial. Females not of childbearing potential must have evidence of such by fulfilling one of the following criteria at screening:Xx_NEWLINE_xXFor women of childbearing potential using a contraceptive pill, an additional barrier method is necessary. A list of adequate contraception methods is provided in the patient information.Xx_NEWLINE_xXPregnant or breast feeding women, or women and men of childbearing potential not willing to use adequate contraception while on treatment and for at least 3 months thereafterXx_NEWLINE_xXWomen of childbearing potential must be non-pregnant and non-lactating and willing to use highly effective form of contraception during radiation therapyXx_NEWLINE_xXPregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraceptionXx_NEWLINE_xXWomen must not be pregnant or breast-feeding due to unknown effects of treatments on the unborn fetus. All women of childbearing potential must have a blood test within 72 hours prior to randomization to rule out pregnancy. Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimized. Sexually mature females who have not undergone a hysterectomy or who have not been postmenopausal naturally for at least 24 consecutive months (i.e., who have had menses at some time in the preceding 24 consecutive months) are considered to be of childbearing potential. Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g.,vasectomy) should be considered to be of childbearing potential.Xx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and azoospermic men do not require contraceptionXx_NEWLINE_xXMen of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months after completion of treatmentXx_NEWLINE_xXMen and women of reproductive potential may not participate unless they agree to use an effective contraceptive methodXx_NEWLINE_xXWomen of child-bearing potential and sexually active men must agree to use adequate contraception (hormonal, barrier method, or abstinence) prior to study entry, during treatment, and for three months after completing treatmentXx_NEWLINE_xXPregnant and breastfeeding women are excluded; women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to 4 weeks after the study are excluded; this applies to any woman who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months, or women on hormone replacement therapy with serum follicle stimulating hormone [FSH] levels greater than 35 mIU/mL); a negative urine or serum pregnancy test must be obtained within 14 days prior to the start of study therapy in all women of child-bearing potential; male subjects must also agree to use effective contraception for the same period as aboveXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must use highly effective method(s) of contraception; WOCBP should use a highly effective method to avoid pregnancy for the duration of this study and for at least 5 months after the last dose of nivolumab; WOCBP and men must agree to use a highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for at least 5 months from the last dose of nivolumab; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men who are sexually active with WOCBP must also use a highly effective contraceptive method for at least 7 months after the last dose of nivolumabXx_NEWLINE_xXWomen of child bearing potential and sexually active males must use an accepted and effective non-hormonal method of contraceptionXx_NEWLINE_xXWomen of child-bearing potential, defined as all women older than age 50 and anovulatory for 12 months, unless they are using highly effective methods of contraception during dosing and for 30 days after study treatmentXx_NEWLINE_xXPregnant women, nursing mothers, men or women of reproductive ability who are unwilling or unable to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to enrollment and initiation of treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 7 days prior to the first dose of study drugs and must agree to use an effective contraception method during the study and for 30 days following the last dose of study drug; women of non- childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy; men who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drugXx_NEWLINE_xXWomen who are pregnant or breast-feeding; NOTE: Premenopausal women on ovarian suppression therapy are still considered of childbearing potential; women of childbearing potential and men must be strongly advised to use an accepted and effective method of non-hormonal contraception; acceptable contraception includes barrier methods (e.g., condoms or diaphragm) or intrauterine devices (IUDs) (these may include low-dose hormones at the discretion of the study chair)Xx_NEWLINE_xXBe of non-reproductive potential ORXx_NEWLINE_xXAny of the following because this study involves an agent where the genotoxic, mutagenic and teratogenic effects are unknown:\r\n* Pregnant or breastfeeding\r\n* Patient of childbearing potential who is unwilling to employ adequate contraceptionXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception beginning at the signing of the consent until at least 3 months after the last dose of study drugXx_NEWLINE_xXWomen of reproductive potential (defined as all women physiologically capable of becoming pregnant) must agree to use suitable methods of contraception for 90 days after the last dose of study therapy (durvalumab or JCAR014)Xx_NEWLINE_xXMeets one of the following criteria: Is post-menopausal, or, Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for four months after stopping medication.Xx_NEWLINE_xXPregnant women, or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period and for up to 4 weeks after the studyXx_NEWLINE_xXPregnant women, or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period and for up to 4 weeks after the studyXx_NEWLINE_xXMen and women must be willing to use appropriate contraception throughout study and for 6 months afterXx_NEWLINE_xXWomen of childbearing potential must agree to use effective contraception without interruption throughout the study and for a further 3 months after the end of treatmentXx_NEWLINE_xXParticipants of childbearing/reproductive potential must use effective contraception.Xx_NEWLINE_xXMen and women of childbearing potential (WOCBP) must be using 2 reliable methods of contraception to avoid pregnancy throughout the study for a period of at least 30 days before and 90 days after the last dose of investigational product in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXSince this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown, any of the following will deem the subject ineligible for the study:\r\n* Pregnant women\r\n* Nursing women\r\n* Men or women of childbearing potential who are unwilling to employ adequate contraceptionXx_NEWLINE_xXDONOR: Women of childbearing potential and men must agree to use adequate contraception with two different forms, including one barrier method, during participation in the study and for 2 weeks following dosing with BL-8040; abstinence is acceptable if this is the established and preferred contraception for the subjectXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use an effective contraception method during the study and for 30 days following the last dose of study drug; women of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy; men who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drugXx_NEWLINE_xXWomen participate in the study must be surgically sterile, post-menopausal, or women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation and after for a certain amount of time\r\n* The individual methods of contraception and duration should be determined in consultation with the investigator; the duration of mandatory contraception is based on clearance of the investigational drug (5 half-lives after treatment completion); for women, an additional 30 days is required to complete an ovulatory cycle; calculation of duration of mandatory contraception: the half-life of cisplatin is 20-30 minutes, half-life of methotrexate is 8-15 hours and half-life of gemcitabine is 42-94 minutes; thus, contraception is required for up to 5 weeks after the last treatment for women of child-bearing potential\r\n* Women must have a negative serum or urine pregnancy test within 24 hours prior to the start of transarterial chemoperfusion treatment\r\n* Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXMen who are sexually active with women of childbearing potential (WOCBP) must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational productXx_NEWLINE_xXWomen of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 14 days prior to the start of nivolumab; women must not be breastfeeding; men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraceptionXx_NEWLINE_xXPregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within 2-6 weeks prior to treatmentXx_NEWLINE_xXSubjects must not be pregnant or breastfeeding; pregnancy tests must be obtained for all females of child-bearing potential; pregnant or lactating patients are ineligible for this study; males or females of reproductive age may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXWomen of childbearing potential (defined as not postmenopausal [ie, ? 12 months of non-therapy-induced amenorrhea] or not surgically sterile) must have a negative serum pregnancy test within 21 days prior to initiation of Toca 511, and be willing to use an effective means of contraception in addition to barrier methods (condoms).Xx_NEWLINE_xXPregnant women, or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period and for up to 4 weeks after the study treatmentXx_NEWLINE_xXPatients must be willing to use contraception if they have childbearing potentialXx_NEWLINE_xXWomen of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 6 months after the last dose of investigational product in such a manner that the risk of pregnancy is minimized; men on study and for at least 6 months after the last dose of nab-paclitaxel also must be using contraception; women of childbearing potential (WOCBP) are women who have not been postmenopausal greater than 1 year or undergone a hysterectomy and/or bilateral oophorectomyXx_NEWLINE_xXWomen of childbearing potential and men should agree to use adequate contraception prior to study entry and for the duration of study participation and women who are breast feeding are excluded from the study; both women and men should be fully informed of the lack of reproductive toxicity testing, and women must have a negative pregnancy test prior to enrollmentXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment; males with sexual partners who are pregnant or who could become pregnant (i.e., women of child-bearing potential) should use effective methods of contraception for 12 weeks after completing the study to avoid pregnancy and/or potential adverse effects on the developing embryoXx_NEWLINE_xXMen or women of childbearing potential who are unwilling to employ adequate contraception\r\n* NOTE: patients unwilling or unable to do any of the following are also excluded:\r\n** Men must agree to use a latex condom during sexual contact with a female of child-bearing potential even if they have had a successful vasectomy\r\n** Women of child bearing potential must agree to use 2 methods of reliable contraception simultaneously\r\n** All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposureXx_NEWLINE_xXThe study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) must use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of study drugXx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraceptionXx_NEWLINE_xXWomen of childbearing potential (WOCBP) receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; these durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days and men who are sexually active with WOCBP use contraception for 5 half-lives plus 90 daysXx_NEWLINE_xXWomen/men of reproductive potential must be counseled on contraception/abstinence while receiving the study treatmentXx_NEWLINE_xXFertile men must practice effective contraceptive methods during the study period, unless documentation of infertility existsXx_NEWLINE_xXFertile men unwilling to practice contraceptive methods during the study periodXx_NEWLINE_xXWomen of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during the study and 8 weeks after; highly effective contraception methods include combination of any two of those listed in the protocolXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; (note: serum pregnancy tests must be obtained in women of child bearing potential); sexually active females may not participate unless they have agreed to use an effective contraceptive method (such as abstinence, diaphragm, condom, or intrauterine device) to prevent pregnancy for the duration of the studyXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG])\r\n* WOCBP must agree to follow instructions for method(s) of contraception from the time of enrollment for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 4 weeks (duration of ovulatory cycle) for a total of 23 weeks post treatment completion\r\n* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment completion\r\n* Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception\r\n* Women must not be breastfeeding\r\n* At least one barrier method of contraception must be employed by all sexually active patients (male and female), regardless of other methods, to prevent the transfer of body fluidsXx_NEWLINE_xXPregnant or nursing women may not participate; women of childbearing potential may not participate unless they have agreed to use an adequate contraceptive method throughout study treatment and for one month after completion of treatmentXx_NEWLINE_xXWomen of child-bearing potential and men must be willing to use adequate contraception during the entire study and for 8 weeks following completion of all chemotherapy on study; this includes hormonal or barrier method, or abstinenceXx_NEWLINE_xXWomen of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must use 2 highly effective methods of contraception while taking study treatment and for 90 days after the last dose of study treatment.Xx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and for 90 days following completion of therapyXx_NEWLINE_xXWomen of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatmentXx_NEWLINE_xXPregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test at baseline; women/men of childbearing potential not using a reliable contraceptive method (oral contraceptive, other hormonal contraceptive, intrauterine device, diaphragm or condom); (postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential); patients must agree to continue contraception for 30 days from the date of the last study drug administrationXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during treatment and for 3 months after stopping treatmentXx_NEWLINE_xXWomen of childbearing potential and men should be advised and agree to practice effective methods of contraception during the course of studyXx_NEWLINE_xXMen of reproductive potential may not participate unless they agree that they will use an effective contraceptive method such as condom/diaphragm, spermicidal foam, etc - until six months after the end of all radiation therapyXx_NEWLINE_xXMale patient whose sexual partner(s) are women of childbearing potential who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXWomen of child-bearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 24 months post-treatment; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\r\n* Women of childbearing potential are required to have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 7 days prior to the first dose of GDC-0449 (serum or urine); a pregnancy test (serum or urine) will be administered every 4 weeks if their menstrual cycles are regular or every 2 weeks if their cycles are irregular while on study within the 24-hour period prior to the administration of GDC-0449; a positive urine test must be confirmed by a serum pregnancy test; prior to dispensing GDC-0449, the investigator must confirm and document the patient’s use of two contraceptive methods, dates of negative pregnancy test, and confirm the patient’s understanding of GDC-0449 cause serious or life-threatening birth defects; patients must continue highly effective contraception during therapy and for 24 months after the last dose of GDC-0449\r\n* Women of childbearing potential are defined as follows:\r\n** Patients with regular menses\r\n** Patients with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding\r\n** Women who have had a tubal ligation\r\n* Women are considered not to be of childbearing potential for the following reasons:\r\n** The patient has undergone hysterectomy and/or bilateral oophorectomy\r\n** The patient is post-menopausal defined by amenorrhea for at least 12 months in a woman > 45 years old\r\n* Male patients should use condoms with spermicide, even after a vasectomy, during sexual intercourse with female partners while being treated with GDC-0449 and for 3 months after the last dose to avoid exposing an embryo or fetus to GDC-0449Xx_NEWLINE_xXFertile men must practice effective contraceptive methods during the study period, unless documentation of infertility existsXx_NEWLINE_xXFertile men unwilling to practice contraceptive methods during the study periodXx_NEWLINE_xXWomen of child bearing potential who refuse or are not able to use a highly effective method of contraception as defined in the study protocol.Xx_NEWLINE_xXMen or women of childbearing potential who are unwilling to employ adequate contraceptionXx_NEWLINE_xXEffective contraception is required while receiving ibrutinib in combination with GA101 - obinutuzumab; for women of childbearing potential and men, effective contraception is required while receiving GA101 – obinutuzumab and for 365 days (12 months) after the last dose of the study drugXx_NEWLINE_xXWomen of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatmentXx_NEWLINE_xXPregnant or breast-feeding patients; men and women of reproductive potential may not participate in this study unless they have agreed to use an effective contraceptive method while in this study; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential); patients must agree to continue contraception for 3 months from the date of the last study drug administrationXx_NEWLINE_xXWomen/men of reproductive potential unwilling or unable to use an effective contraceptive methodXx_NEWLINE_xXWomen/men of reproductive potential must be counseled on contraception/abstinence while receiving the study treatmentXx_NEWLINE_xXNursing women, women of childbearing potential with positive blood pregnancy test within 30 days of study start, or women of childbearing potential who are not willing to maintain adequate contraception (such as birth control pills, intrauterine device [IUD], diaphragm, abstinence, or condoms by their partner) over the entire course of the studyXx_NEWLINE_xXAny of the following\r\n* Pregnant women\r\n* Nursing women\r\n* Women of childbearing potential who are unwilling to employ highly effective contraception while on study treatment and for 6 months after the final dose of treatment; NOTE: women of childbearing potential are defined as all women physiologically capable of becoming pregnant\r\n* Men of childbearing potential who are unwilling to employ highly effective contraception while on study treatment and for 6 months after the final dose of treatment and should not father a child during this time; NOTE: men of childbearing potential are defined as all males physiologically capable of conceiving offspringXx_NEWLINE_xXFertile men must practice effective contraceptive methods during the study, unless documentation of infertility existsXx_NEWLINE_xXFertile men unwilling to practice contraceptive methods during the study periodXx_NEWLINE_xXPregnant or nursing women; men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXPatients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after the trialXx_NEWLINE_xXFertile men must practice effective contraceptive methods during the study, unless documentation of infertility existsXx_NEWLINE_xXFertile men unwilling to practice contraceptive methods during the study periodXx_NEWLINE_xXFertile men and women unwilling to use contraceptive techniques during and for 12 months following treatmentXx_NEWLINE_xXMen and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafterXx_NEWLINE_xXMen and women of childbearing potential who do not practice contraception; women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participationXx_NEWLINE_xXFor women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of MK-3475Xx_NEWLINE_xXPatients who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of child-bearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; women of childbearing potential are required to have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 10-14 days prior to the first vaccine, within 24 hours prior to the first and second doses of vaccine and prior to surgery\r\n* Women of childbearing potential are defined as follows:\r\n** Patients with regular menses\r\n** Patients with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding\r\n** Women who have had a tubal ligation\r\n* Women are considered not to be of childbearing potential for the following reasons:\r\n** The patient has undergone hysterectomy and/or bilateral oophorectomy\r\n** The patient is post-menopausal defined by amenorrhea for at least 1 year in a woman > 45 years oldXx_NEWLINE_xXPersons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 26 weeks after ipilimumab is stopped; sexually active WOCBP must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; all WOCBP MUST have a negative pregnancy test before first receiving ipilimumab; if the pregnancy test is positive, the patient must not receive ipilimumab and must not be enrolled in the studyXx_NEWLINE_xXPregnant or lactating patients; patients of childbearing potential must implement contraceptive measures during study treatment and for 7 months after the last dose of the study drugXx_NEWLINE_xXFertile men must practice effective contraceptive methods during the study, unless documentation of infertility existsXx_NEWLINE_xXFertile men unwilling to practice contraceptive methods during the study periodXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of study treatment and must be willing to use two methods of contraception one of them being a barrier method during the study and for 3 months after last study drug administrationXx_NEWLINE_xXPatients must not be pregnant or breastfeeding; pregnancy tests must be obtained for all females of child-bearing potential; pregnant or lactating patients are ineligible for this study; males or females of reproductive age may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXAll patients of childbearing potential must be willing to use a contraceptive method before, during, and for at least two months after the T cell infusionXx_NEWLINE_xXWomen of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatmentXx_NEWLINE_xXWomen of childbearing potential and male participants must practice adequate contraceptionXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 months after pasireotide s.c. last dose and 3 months after pasireotide LAR last dose Highly effective contraception methods include:Xx_NEWLINE_xXSubjects of childbearing potential who are unwilling to take appropriate precautions (from screening through follow-up) to avoid becoming pregnant or fathering a child; females of non-childbearing potential are defined as women who a) are 55 years of age with history of amenorrhea for 1 year OR b) are surgically sterile for at least 3 months; for females of childbearing potential, or for males, pregnancy must be avoided by taking appropriate precautions; these precautions and the methods of contraception should be communicated to the subjects and their understanding confirmedXx_NEWLINE_xXFertile men must practice effective contraceptive methods during the study, unless documentation of infertility existsXx_NEWLINE_xXFertile men unwilling to practice contraceptive methods during the study periodXx_NEWLINE_xXPatients must be willing to use contraception if they have childbearing potentialXx_NEWLINE_xXWomen of childbearing potential and men must agree to using medically approved (i.e., mechanical or pharmacological) contraceptive measure for at least 112 days following the last dose of sotatercept (ACE-011); males must agree to use a latex condom or non-latex condom NOT made of natural (animal) membrane during any sexual contact with females of childbearing potential or a pregnant female while participating in the study and for at least 112 days following the last dose of sotatercept (ACE-011), even if he has a vasectomyXx_NEWLINE_xXIf female and of childbearing potential, have a negative serum or urine pregnancy test during screening. Agree to use a barrier method of contraception if sexually active (both men and women) from the time of administration of the first treatment and for at least 8 weeks after treatment.Xx_NEWLINE_xXPregnant or nursing women are ineligible and patients of reproductive potential must agree to use an effective contraceptive method during participation in this trialXx_NEWLINE_xXPatients of childbearing potential must practice appropriate contraceptionXx_NEWLINE_xXPersons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped; women of childbearing potential and men with a sexual partner of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancyXx_NEWLINE_xXSex and reproductive status:\r\n* Women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after the last dose of study drug\r\n* Women who are pregnant or breastfeeding\r\n* Women with a positive pregnancy test\r\n* Sexually active fertile men not using effective birth control if their partners are WOCBPXx_NEWLINE_xXWillingness to comply with an appropriate contraceptive method in women of childbearing potential or men.Xx_NEWLINE_xXUse of effective means of contraception (men and women) in subjects of child-bearing potentialXx_NEWLINE_xXWomen of childbearing potential (WOCBP) and fertile men with partners of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 26 weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; (note: serum pregnancy tests must be obtained in women of child bearing potential); sexually active females may not participate unless they have agreed to use an effective contraceptive method (such as abstinence, diaphragm, condom, or intrauterine device) to prevent pregnancy for the duration of the studyXx_NEWLINE_xXMen and women of childbearing potential who do not practice contraception; women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participationXx_NEWLINE_xXMen and women of childbearing potential should practice 2 methods of contraception; 1 method must be highly effective and a second method must be either highly effective or less effective; men and women of childbearing potential are defined as: a male that has not been surgically sterilized or a female that has not been amenorrheic for at least 12 consecutive months or that has not been surgically sterilized; patients must use birth control during the study and for 3 months after the last dose of study drug if they are sexually activeXx_NEWLINE_xXMen and women enrolled in the protocol must agree to use adequate contraceptive measure when the female (patient, or partner of the male patient) has childbearing potential (the woman is not postmenopausal and has an intact uterus)Xx_NEWLINE_xXMen or women.Xx_NEWLINE_xXFertile men or women unwilling to use contraceptive techniques during and for 12 months following treatmentXx_NEWLINE_xXPregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception; women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months; in addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth controlXx_NEWLINE_xXFertile men should be willing to use barrier contraception during and for 4 months after AZD9291 (osimertinib), and fertile women must agree to use adequate contraceptive measures during and for 6 weeks after AZD9291 (osimertinib); fertile men and women must agree to use adequate contraceptive measures during study therapy and for at least 6 months after the completion of bevacizumab therapy; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the patient should inform the treating physician immediatelyXx_NEWLINE_xXSexually active females of childbearing potential and sexually active males with partners of reproductive potential: unwilling or unable to use appropriate contraception from screening until at least 6 months after last administration of study treatment.Xx_NEWLINE_xXPregnant or breast-feeding; for males and females of child-producing potential, inability to use effective contraceptive methods during the studyXx_NEWLINE_xXMen or women not using effective contraceptionXx_NEWLINE_xXPatients must be willing to use contraception if they have childbearing potentialXx_NEWLINE_xXPatient must not be pregnant because of the risk of harm to the fetus; nursing women may participate only if nursing is discontinued, due to the possibility of harm to nursing infants from the treatment regimen; women/men of reproductive potential must agree to use an effective contraception methodXx_NEWLINE_xXPregnant women, or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period and for up to 4 weeks after the study treatmentXx_NEWLINE_xXPatients must be willing to use contraception if they have childbearing potentialXx_NEWLINE_xXWomen of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during the study and 8 weeks after; highly effective contraception methods include combination of any two of the following:Xx_NEWLINE_xXWomen of reproductive potential must agree to use an effective non-hormonal method of contraception during therapyXx_NEWLINE_xXFertile men or women unwilling to use contraceptive techniques during and for 12 months following treatmentXx_NEWLINE_xXpatients who are not pregnant, committed to using adequate contraception if of childbearing ageXx_NEWLINE_xXPregnant women are excluded and pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method from the time of study entry to a period of no less than four months post the final HSV1716 dose; for the same period of time, women who participate in this study must agree not to breast feedXx_NEWLINE_xXNon-pregnant and non-nursing; men and women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on the studyXx_NEWLINE_xXMen and Women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 3 months after the study. Subjects who are men must also agree to use effective contraception. Note: WOCBP must be using an adequate method of contraception throughout the study and for up to 3 months after the study. Adequate methods of contraception will include (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner).Xx_NEWLINE_xXWomen of childbearing potential and sexually active males should use effective contraception while on studyXx_NEWLINE_xXWomen of childbearing potential and sexually active males should use effective contraception while on studyXx_NEWLINE_xXAll men and women of reproductive potential must agree to practice effective contraception for 4 weeks prior to study entry, during the entire study period and for one month after the study unless documentation of infertility existsXx_NEWLINE_xXPregnant women may not participate; women of childbearing potential and sexually active males will be advised to effective contraception while on studyXx_NEWLINE_xXPregnant women may not participate; women of childbearing potential and sexually active males will be advised to use effective contraception while on studyXx_NEWLINE_xXWomen who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug. Women of childbearing potential (WOCBP) and fertile men with WOCBP-partner(s) not using and not willing to use a highly effective method of contraception.Xx_NEWLINE_xXPregnant or lactating women; women of childbearing potential must use effective contraception methods prior to study entry, for the duration of study participation, and for 6 months after the last dose of MCLA-128.Xx_NEWLINE_xXWomen/men of childbearing potential must have agreed to use a highly effective contraceptive method during and for 6 months after completion of chemotherapy.Xx_NEWLINE_xXWomen of childbearing potential and males must be willing to use an effective method of contraception from the time consent is signed until 4 weeks after treatment discontinuationXx_NEWLINE_xXWomen of child-bearing potential and men must agree to use adequate contraception prior to the start of treatment, for the duration of treatment, and for 5 months after last dose of study treatmentXx_NEWLINE_xXchildbearing potential without proper contraceptive measures, pregnancy, or breast feeding;Xx_NEWLINE_xXFor men and women of child-bearing potential, willing to use adequate contraception (i.e., latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study.Xx_NEWLINE_xXFemales: Pregnant or breast?feeding women, or women of childbearing potential unless effective method of contraception is used during and for 3 months after the trial. Males: unless an effective method of contraception is used during and for 3 months after the trial.Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative serum beta-HCG pregnancy test result within seven days of treatment and must practice an effective method of contraception during treatment and for at least 9 months (270 days) following the last dose of study drug.Xx_NEWLINE_xXWomen of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 3 months afer stopping ceritinib treatment.Xx_NEWLINE_xXWomen of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period.Xx_NEWLINE_xXMen of fathering potential must be using an adequate method of contraception to avoid conception throughout the study [and for up to 26 weeks after the last dose of investigational product] in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXWomen of childbearing potential and sexually active males must commit to the use of adequate contraception from the study start to one year after the last dose of study treatmentXx_NEWLINE_xXPregnant or breast feeding women, or women and men of childbearing potential not willing to use adequate contraception while on treatment and for at least 3 months thereafterXx_NEWLINE_xXAgrees to contraceptive use while on study if sexually activeXx_NEWLINE_xXThe effects of AR-67 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason women of child-bearing potential (i.e., not post-menopausal for at least 12 months and not surgically sterile) and men must agree to use effective methods of contraception. Women of childbearing potential (any women who is not surgically sterile or > 2 years post menopause) must give consent for using a reliable method of contraception (e.g. double-barrier, tubal ligation or stable hormonal contraception) throughout the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.Xx_NEWLINE_xXFor men and women of child-producing potential, use of effective contraceptive methods during the studyXx_NEWLINE_xXFertile men and women must agree to use a medically effective contraception method throughout the treatment period. Premenopausal women of reproductive capacity and women less than 24 months post menopause must have a negative serum pregnancy test documented prior to study entryXx_NEWLINE_xXFemales who are of childbearing potential must practice effective contraception and meet the following criteria:Xx_NEWLINE_xXMen or women.Xx_NEWLINE_xXFemale subjects: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female subject is eligible to participate if she is not pregnant or breastfeeding, and not a woman of childbearing potential (WOCBP) or is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency, during the intervention period and for at least 80 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention.Xx_NEWLINE_xXSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for 4 months after the last dose of veliparibXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraceptionXx_NEWLINE_xXSigned written informed consent forms HLA SCREENING: • Women of childbearing potential must use adequate contraception MAIN SCREENING:Xx_NEWLINE_xXPregnant women or women who are of child bearing age who are not willing to use two (2) forms of contraception during treatment with enzalutamide and for six (6) months after treatmentXx_NEWLINE_xXWomen of child-bearing potential defined as all women physiologically capable of becoming pregnant who are unwilling to use highly effective methods of contraception throughout the study and 15 days after study drug discontinuationXx_NEWLINE_xXWomen of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period.Xx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): Women of childbearing potential and sexually active males must use an accepted and effective method of contraception or to abstain from sex from time of registration, while on study treatment, and continue for 120 days after the last dose of study treatmentXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 2): Women of childbearing potential and sexually active males must use an accepted and effective method of contraception or to abstain from sex from time of registration, while on study treatment, and continue for 120 days after the last dose of study treatmentXx_NEWLINE_xXSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation; women of childbearing potential must have a negative pregnancy test done within 7 days prior to registrationXx_NEWLINE_xXMales and females of reproductive age and childbearing potential must use effective contraception for the duration of their participationXx_NEWLINE_xXMale or female patients of childbearing potential must be willing to use contraceptive precautions throughout the trial and 3 months following discontinuation of study treatment. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.Xx_NEWLINE_xXPregnancy or breast-feeding: Female patients who are pregnant are ineligible for study; lactating females are not eligible unless they have agreed not to breastfeed their infants from the time of informed consent through the duration and at least 1 month following the study; female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained; sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method from the time of informed consent through the duration and for 1 month following study participation; the definition of an effective contraceptive method will be at the discretion of the institutional investigatorXx_NEWLINE_xXPatients with reproductive potential declining to use an effective contraceptive method during treatment are excluded from this study.Xx_NEWLINE_xXPatients who are sexually active must use medically acceptable forms of contraceptionXx_NEWLINE_xXMen or women of reproductive ability who are unwilling to use effective contraception and women of childbearing potential who are unwilling to undergo pregnancy testing before and during the study.Xx_NEWLINE_xXENROLLMENT: Sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the investigator. (Non-childbearing potential defined as pre-menarche, greater than one year post-menopausal or surgically sterilized).Xx_NEWLINE_xXFertile men must practice effective contraceptive methods during the study, unless documentation of infertility existsXx_NEWLINE_xXFertile men unwilling to practice contraceptive methods during the study periodXx_NEWLINE_xXMen and women of childbearing potential must be willing to use adequate contraception throughout the study and for 3 weeks after study drug discontinuationXx_NEWLINE_xXAny of the following:\r\n* Pregnant individuals\r\n* Nursing individuals\r\n* Persons of childbearing potential who are unwilling to employ adequate contraceptionXx_NEWLINE_xXPregnant or nursing women; men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. Suggested precautions should be used to minimize the risk or pregnancy for at least 1 month before start of therapy, and while women are on study for up to 3 months after T cell infusion, and at least 8 weeks after the study drug is stopped.Xx_NEWLINE_xXPregnant or lactating women; women of childbearing potential not using a reliable and appropriate contraceptive method; postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential; patients will agree to continue the use of acceptable form of contraception for 30 days from the date of last drug administrationXx_NEWLINE_xXPregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception; women of childbearing potential with a positive pregnancy test within 3 days prior to entryXx_NEWLINE_xXMen and women of childbearing potential who do not practice contraception; women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participationXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test and must agree to the use of effective contraception while on treatment; men must also agree to the use of effective contraception while on treatmentXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies; pregnancy tests must be obtained in women; sexually active males or females may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatmentXx_NEWLINE_xXWomen of childbearing potential must use highly effective methods of contraception throughout the study and for 4 months after study drug discontinuationXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXIf female with reproductive potential, must have a negative serum pregnancy test prior to the start of study therapy. Females of reproductive potential, as well as fertile men and their female partners of reproductive potential, must agree to use 2 effective forms of contraception.Xx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 2 months after the last dose of RO6870810 as monotherapy, or for at least 3 months after the last dose of daratumumab.Xx_NEWLINE_xXFor men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm, as defined: With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 4 months after the last dose of RO6870810 as monotherapy, or for at least 3 months after the last dose of daratumumab.Xx_NEWLINE_xXWomen of childbearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of childbearing potential and men with female partners of childbearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child while receiving treatment with guadecitabine, LDAC, or IC and for at least 3 months after completing treatment.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to registration\r\n* Note: women of child-bearing potential (WOCBP) must use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (<) 1 percent (%) per year during the treatment period and for at least 30 days after the last dose of guadecitabine or 5 months after the last dose of atezolizumab, whichever is longerXx_NEWLINE_xXSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation; patients should maintain adequate contraception for a minimum of 2 months after the last dose of ch14.18 (dinutuximab)Xx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for at least one week prior to the start of the research study, and continuing for 5 months for women of childbearing potential and 7 months for sexually active males after the last dose of the study drugsXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during treatment and for 6 months after the last dose of cetuximab or MEDI14736 (durvalumab); this exclusion is necessary because the treatment involved in this study may be significantly teratogenic; women who are breastfeeding are also excludedXx_NEWLINE_xXWomen of child bearing potential and men must agree to remain abstinent or use adequate contraception (failure rate < 1%) for the duration of study and for 90 days after the completion of the therapyXx_NEWLINE_xXWomen of childbearing potential should be advised to avoid becoming pregnant while receiving InO; women should not breast-feed during treatment with InO and for at least 2 months after the final dose\r\n* Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained within 7 days of starting protocol therapy\r\n* Female patients who are sexually active and of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of their study participation and for 8 months after the last dose of InO\r\n* Men with female partners of childbearing potential should use effective contraception during treatment with InO and for at least 5 months after the last dose of InO\r\n* Lactating females are not eligible unless they agree not to breastfeed their infantsXx_NEWLINE_xXFemale patients of childbearing potential and men receiving MK-3475 (pembrolizumab) who are sexually active with women of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of MK-3475 (pembrolizumab); note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patientXx_NEWLINE_xXFor women of childbearing potential and men: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive measures For participants in Cohorts A, A2, B, and B2:Xx_NEWLINE_xXPatients who are pregnant or breast-feeding are not eligible for this study; negative pregnancy tests must be obtained in girls who are postmenarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study therapy and for 3 months after the last dose of GD2Bi-aATC; breastfeeding women should be excludedXx_NEWLINE_xXSexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participationXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participationXx_NEWLINE_xXMen of reproductive potential who are sexually active with women of reproductive potential must use any contraceptive method with a failure rate of less than 1% per year; men who are receiving the study medications will be instructed to adhere to contraception for 31 weeks after the last dose of study drugs; men who are azoospermic do not require contraceptionXx_NEWLINE_xXSubjects must not be pregnant or breastfeeding; pregnancy tests must be obtained for all females of child-bearing potential; pregnant or lactating patients are ineligible for this study; males or women of childbearing potential may not participate unless they have agreed to use an effective contraceptive method (defined as hormonal contraceptives, intrauterine devices, surgical contraceptives, or condoms)Xx_NEWLINE_xXWomen of childbearing potential must be willing to abstain from heterosexual activity or use an effective method of contraception from the time of informed consent until 5 months after treatment discontinuation. Women cannot breast feed from the time of informed consent to 5 months after last dose of study treatment.Xx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product.Xx_NEWLINE_xXBoth women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must agree to use 2 highly effective methods of contraception as outlined in this protocol for the duration of treatment with study drug plus 5 half-lives of study drug plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment completionXx_NEWLINE_xXSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for 6 months after the last dose of chemotherapyXx_NEWLINE_xXFemales of childbearing potential, and males, must be willing to use an effective method of contraceptionXx_NEWLINE_xXWomen of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 31 weeks after the last dose of investigational drug; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab; women must not be breastfeeding; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) do not require contraception\r\n* Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL\r\n* WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; these durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days\r\n* Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform the treating physician immediatelyXx_NEWLINE_xXFertile men or women unwilling to use contraceptive techniques during and for 12 months following transplantXx_NEWLINE_xXQuantitative serum b-HCG must be negative in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; pregnant or breast-feeding women will not be entered on this studyXx_NEWLINE_xXWomen who are pregnant or lactating, or who are of childbearing potential , and men\n             who do not use a barrier methodXx_NEWLINE_xXINCLUSION CRITERIA:\n\n        Patients must meet all of the inclusion criteria outlined below in order to be eligible to\n        participate in the study.\n\n          1. Patients with histologically and/or cytologically confirmed solid tumors who have\n             progressed after receiving approved therapies for their disease and for whom no\n             effective therapies are available.\n\n          2. Surgery and radiotherapy must have been completed at least four weeks prior to study\n             entry, and prior chemotherapy and other anti-cancer therapy, excluding\n             bisphosphonates at a steady dose level, must have been discontinued 2 to 3 weeks\n             previously. All acute toxicities related to these treatments must have resolved.\n\n          3. Aged ? 18 years\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\n          5. Written informed consent prior to any study specific screening procedures, which will\n             include mandatory consent to provide a blood sample specifically for pharmacogenomic\n             analysis, with the understanding that the patient may withdraw consent at any time\n             without prejudice. Tumor biopsy for pharmacogenomic (PG) analysis will be voluntary.\n\n          6. Willing and able to comply with the protocol for the duration of the study.\n\n          7. Anticipated life expectancy > three months.\n\n        EXCLUSION CRITERIA:\n\n        Patients with the following characteristics will not be eligible for the study.\n\n          1. Symptomatic or progressive brain tumors or brain or leptomeningeal (CNS) metastases\n             requiring clinical intervention, except if they have completed local therapy and have\n             discontinued the use of corticosteroids for this indication for at least two weeks\n             before starting treatment with E7107.\n\n          2. Any of the following laboratory parameters:\n\n               1. hemoglobin < 9 g/dL (5.6 mM)\n\n               2. neutrophils < 1.5 x 10^9/L\n\n               3. platelets < 100 x 10^9/L\n\n               4. serum bilirubin > 25 ?M (1.5 mg/dL)\n\n               5. liver function tests (defined as AST and ALT) with values > 3 x ULN (5 x ULN if\n                  liver metastases are present)\n\n               6. serum creatinine > 1.5 x ULN or creatinine clearance < 40 mL/min.\n\n          3. Positive history of HIV, active hepatitis B or active hepatitis C or\n             severe/uncontrolled intercurrent illness or infection.\n\n          4. Clinically significant cardiac impairment or unstable ischemic heart disease (greater\n             than Class II according to New York Heart Association (NYHA) classification)\n             including a myocardial infarction within six months of study start.\n\n          5. Bleeding or thrombotic disorders, or using therapeutic dosages of anticoagulants\n\n          6. History of alcoholism, drug addiction, or any psychiatric or psychological condition\n             which, in the opinion of the Investigator, would impair study compliance.\n\n          7. Women who are pregnant or breast-feeding. Women of childbearing potential with either\n             a positive serum pregnancy test at screening, a positive urine pregnancy test at the\n             beginning of any cycle, or no pregnancy test. Women of childbearing potential unless\n             using two forms of contraception, one of which must be a barrier method.\n             Postmenopausal women must be amenorrheic for at least 12 months to be considered of\n             non-childbearing potential.\n\n          8. Fertile men and fertile women who are not willing to use contraception, or fertile\n             men or fertile women with a partner who is not willing to use contraception\n\n          9. Patients with a marked screening or baseline prolongation of QT/QTc interval using\n             the Fridericia formula (ie, repeated demonstration of a QTc interval > 450 msec); a\n             history of additional risk factors for Torsade de Pointe (e.g., heart failure,\n             hypokalaemia, history of Long QT Syndrome).\n\n         10. Patients who have had radiation to >= 25% of their bone marrow (e.g., pelvic\n             radiation).\n\n         11. Patients who have a history of previous Grade 2 or higher hypersensitivity to\n             pladienolide B or derivatives and excipients of the formulation\n\n         12. Patients with significant comorbid disease or condition, which in the Investigator's\n             opinion would exclude the patient from the study\n\n         13. Patients who have received an organ allograft ie, requiring immunosuppressive therapy\n\n         14. Beginning two weeks prior to dosing, patients are not allowed to take drugs that are\n             strong CYP inhibitors (including grapefruit juice and herbal supplements) or inducers\n             (including herbal supplements), or are metabolized by cytochrome P (CYPs) and known\n             to have a narrowXx_NEWLINE_xXINCLUSION CRITERIA:\n\n        Patients must meet all of the inclusion criteria outlined below in order to be eligible to\n        participate in the study.\n\n          1. Patients with histologically and/or cytologically confirmed solid tumors who have\n             progressed after receiving approved therapies for their disease and for whom no\n             effective therapies are available.\n\n          2. Surgery and radiotherapy must have been completed at least four weeks prior to study\n             entry, and prior chemotherapy and other anti-cancer therapy, excluding\n             bisphosphonates at a steady dose level, must have been discontinued 2 to 3 weeks\n             previously. All acute toxicities related to these treatments must have resolved.\n\n          3. Aged ? 18 years\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\n          5. Written informed consent prior to any study specific screening procedures, which will\n             include mandatory consent to provide a blood sample specifically for pharmacogenomic\n             analysis, with the understanding that the patient may withdraw consent at any time\n             without prejudice. Tumor biopsy for pharmacogenomic (PG) analysis will be voluntary.\n\n          6. Willing and able to comply with the protocol for the duration of the study.\n\n          7. Anticipated life expectancy > three months.\n\n        EXCLUSION CRITERIA:\n\n        Patients with the following characteristics will not be eligible for the study.\n\n          1. Symptomatic or progressive brain tumors or brain or leptomeningeal (CNS) metastases\n             requiring clinical intervention, except if they have completed local therapy and have\n             discontinued the use of corticosteroids for this indication for at least two weeks\n             before starting treatment with E7107.\n\n          2. Any of the following laboratory parameters:\n\n               1. hemoglobin < 9 g/dL (5.6 mM)\n\n               2. neutrophils < 1.5 x 10^9/L\n\n               3. platelets < 100 x 10^9/L\n\n               4. serum bilirubin > 25 ?M (1.5 mg/dL)\n\n               5. liver function tests (defined as AST and ALT) with values > 3 x ULN (5 x ULN if\n                  liver metastases are present)\n\n               6. serum creatinine > 1.5 x ULN or creatinine clearance < 40 mL/min.\n\n          3. Positive history of HIV, active hepatitis B or active hepatitis C or\n             severe/uncontrolled intercurrent illness or infection.\n\n          4. Clinically significant cardiac impairment or unstable ischemic heart disease (greater\n             than Class II according to New York Heart Association (NYHA) classification)\n             including a myocardial infarction within six months of study start.\n\n          5. Bleeding or thrombotic disorders, or using therapeutic dosages of anticoagulants\n\n          6. History of alcoholism, drug addiction, or any psychiatric or psychological condition\n             which, in the opinion of the Investigator, would impair study compliance.\n\n          7. Women who are pregnant or breast-feeding. Women of childbearing potential with either\n             a positive serum pregnancy test at screening, a positive urine pregnancy test at the\n             beginning of any cycle, or no pregnancy test. Women of childbearing potential unless\n             using two forms of contraception, one of which must be a barrier method.\n             Postmenopausal women must be amenorrheic for at least 12 months to be considered of\n             non-childbearing potential.\n\n          8. Fertile men and fertile women who are not willing to use contraception, or fertile\n             men or fertile women with a partner who is not willing to use contraception\n\n          9. Patients with a marked screening or baseline prolongation of QT/QTc interval using\n             the Fridericia formula (ie, repeated demonstration of a QTc interval > 450 msec); a\n             history of additional risk factors for Torsade de Pointe (e.g., heart failure,\n             hypokalaemia, history of Long QT Syndrome).\n\n         10. Patients who have had radiation to >= 25% of their bone marrow (e.g., pelvic\n             radiation).\n\n         11. Patients who have a history of previous Grade 2 or higher hypersensitivity to\n             pladienolide B or derivatives and excipients of the formulation\n\n         12. Patients with significant comorbid disease or condition, which in the Investigator's\n             opinion would exclude the patient from the study\n\n         13. Patients who have received an organ allograft ie, requiring immunosuppressive therapy\n\n         14. Beginning two weeks prior to dosing, patients are not allowed to take drugs that are\n             strong CYP inhibitors (including grapefruit juice and herbal supplements) or inducers\n             (including herbal supplements), or are metabolized by cytochrome P (CYPs) and known\n             to have a narrowXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXPregnant women will not be entered on this study; pregnancy tests must be obtained in female patients who are post-menarchal; lactating females may not participate unless they have agreed not to breastfeed their infants; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of the study treatmentXx_NEWLINE_xXSexually active men with partners of women of childbearing potential must agree to practice effective methods of contraception during the study and for 6 months after the last treatmentXx_NEWLINE_xXWomen of child bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for 3 months thereafterXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXIs pregnant; women of childbearing potential and male participants unwilling to practice adequate contraceptionXx_NEWLINE_xXPatients who are pregnant or breast-feeding are not eligible for this study; negative pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study therapy and for 4 weeks after the last dose of study therapy; breastfeeding women are excludedXx_NEWLINE_xXAgreement to use adequate contraception: women of child-bearing potential must use contraception prior to study entry and for six months after study participation; men that are sexually active whose partners are women of childbearing age must use condomsXx_NEWLINE_xXWomen of childbearing potential and male subjects must practice adequate contraceptionXx_NEWLINE_xXPatients who are pregnant or nursing; women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug; WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IV/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab; women must not be breastfeeding\r\n* Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile or have undergone definitive radiation) do not require contraception\r\n* Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy of bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 month amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level greater than 40 mIU/mL\r\n* WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product\r\n* Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform the treating physician immediatelyXx_NEWLINE_xXWomen of childbearing potential and male participants must practice adequate contraception throughout the studyXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective double barrier contraceptive method for the entire period in which they are receiving protocol therapy and up to 6 months after treatmentXx_NEWLINE_xXWomen must not be pregnant or breastfeeding; all women of childbearing potential must have a blood test within 72 hours to rule out pregnancy; women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception; women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for 26 weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimized; sexually mature females who have not undergone a hysterectomy or who have not been postmenopausal naturally for at least 24 consecutive months (i.e., who have had menses at some time in the preceding 24 consecutive months) are considered to be of childbearing potential; women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g., vasectomy) should be considered to be of childbearing potentialXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXWomen of child-bearing potential must agree to use adequate contraception, defined as complete abstinence from intercourse with men or two methodsXx_NEWLINE_xXPregnancy or breastfeeding (women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable); radiation therapy is also contraindicated in pregnancyXx_NEWLINE_xXReproductive potential must be either terminated (by surgery, radiation, or menopause) or attenuated by the use of an approved contraceptive method during and for 3 to 6 months following the studyXx_NEWLINE_xXThe study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable); these potential risks may also apply to GSK2141795Xx_NEWLINE_xXPatients who are pregnant or nursing; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; if a patient becomes pregnant while the patient receives trametinib and/or GSK2141795, the potential hazard to the fetus should be explained to the patientXx_NEWLINE_xXWomen of childbearing potential and male participants must practice adequate contraception during protocol treatment and for at least 6 months following treatmentXx_NEWLINE_xXPregnancy or women of childbearing potential, women who cannot discontinue breastfeeding and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXWomen of childbearing potential and sexually active males must use an accepted and\n             effective method of contraception throughout the study and for 8 weeks after\n             completion of the study.Xx_NEWLINE_xXMale patient whose sexual partner(s) are women of childbearing potential (WOCBP) who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXFertile men must practice effective contraceptive methods during the study period, unless documentation of infertility existsXx_NEWLINE_xXFertile men unwilling to practice contraceptive methods during the study periodXx_NEWLINE_xXWomen of childbearing potential must be non-pregnant (negative pregnancy test within 72 hours prior to registration; postmenopausal woman must have been amenorrheic and nonlactating for at least 12 months to be considered of non-childbearing potential; men and women of child bearing potential must be willing to exercise an effective form of birth control (abstinence/contraception) while on study and for 3 months after therapy is completedXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraceptionXx_NEWLINE_xXPHASE II: Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraceptionXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during treatment and for 3 months after stopping treatmentXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test prior to first receiving investigational product; sexually active women of childbearing potential (WOCBP) must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; all WOCBP should be instructed to contact the investigator immediately if they suspect they might be pregnant (e.g., missed or late menstrual period) at any time during study participationXx_NEWLINE_xXPregnant or lactating women; patients in reproductive age must agree to use contraceptive methods for the duration of the study (a pregnancy test will be obtained before treatment)Xx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXDONOR: Breast feeding or pregnant females; donors of childbearing potential must use an effective method of contraception during the time they are receiving filgrastimXx_NEWLINE_xXWomen of childbearing potential and male participants who are sexually active must agree to practice adequate contraception during treatment and for 6 months post-treatmentXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXPregnant or nursing women or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXFertile men and women unwilling to use contraceptive techniques from the time of transplant until one month post maintenance therapyXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during the trial and for 6 months after completion of treatmentXx_NEWLINE_xXWomen of childbearing potential and sexually active males must use contraception while on studyXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXMen of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter, which should be for at least 6 months after the completion of protocol therapyXx_NEWLINE_xXSubjects who are women of childbearing potential and sexually active males must be willing to use effective contraception while on studyXx_NEWLINE_xXFertile men or women who are unwilling to use contraceptives during HCT and up to 12 months post-treatmentXx_NEWLINE_xXPregnant or lactating; patients of childbearing potential must use an effective method of contraceptionXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXPatients must not be pregnant or nursing; women of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXSubjects who are pregnant, lactating or of reproductive potential and not practicing an effective means of contraceptionXx_NEWLINE_xXWomen who are pregnant or lactating or refuse to commit to use contraception anytime during the studyXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must agree to use an effective contraceptive method during and for 6 months after completing protocol treatment; a negative pregnancy test (either serum or urine) is required within 7 days prior to registration; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method during the study period; a woman is considered to be \of reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXWomen of childbearing potential and sexually active males must use an accepted and effective method of contraception or agree to abstain from sexual intercourse during their participation in the study and for 3 months following completion of their participationXx_NEWLINE_xXWomen of child-bearing potential unless they are using highly effective methods of contraception during the study treatment and for 21 days after stopping the study treatment.Xx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 7 days from day 1 of study drug; both men and women must be willing to use two methods of contraception, one of them being a barrier method during the study and for 6 months after last study drug administrationXx_NEWLINE_xXWomen of childbearing potential must have a negative urine or serum pregnancy test within 28 days prior to registration; women/men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 120 days after the last dose of study medication; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures, he/she is responsible for beginning contraceptive measures; patients must not be pregnant or nursingXx_NEWLINE_xXIn case of use of oral contraception, women must be stable on the same pill for a minimum of 3 months before taking study treatment. Women who are not of reproductive potential (defined as either <11 years of age, Tanner Stage 1, post-menopausal for at least 24 consecutive months (i.e. have had no menses) or have undergone hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy) are eligible without requiring the use of contraception. Women who are not yet of reproductive potential are to agree to use acceptable forms of contraception when they reach reproductive potential if within 1 year of CTL019 or if CAR cells are present in the blood by PCR. Acceptable documentation includes written or oral documentation communicated by clinician or clinician's staff of one of the following:Xx_NEWLINE_xXCLINICAL/LABORATORY CRITERIA: Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation and for 4 months after the last dose of the drug; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXWomen of child-bearing potential (defined as all women physiologically capable of becoming pregnant) and all male participants must agree to use highly effective methods of contraception for at least 12 months following CTL019 infusion and until CAR T cells are no longer present by PCR on two consecutive testsXx_NEWLINE_xXWomen of childbearing potential who are sexually active should be willing and able to use medically acceptable forms of contraception throughout the treatment phase of the trial and for up to 6 months following the last administration of study treatment; men who are sexually active must be willing and able to use medically acceptable forms of contraception throughout the treatment phase of the trial and for 6 months after completion of M6620 (VX-970) administrationXx_NEWLINE_xXWomen of childbearing potential and men with partners of childbearing potential must be willing to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for 7 months after the last dose of study treatmentXx_NEWLINE_xXWomen of child-bearing potential and men must use an acceptable method of contraception during treatment and for 23 weeks after treatment for women and 31 weeks for menXx_NEWLINE_xXWomen with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use effective contraceptive method; reliable contraception should be used from trial screening and must be continued throughout the study; a woman of childbearing potential is defined as one who is biologically capable of becoming pregnantXx_NEWLINE_xXDocumented willingness to use an effective means of contraception for both men and women while participating in the studyXx_NEWLINE_xXPatients with reproductive potential must use an effective method to avoid pregnancy for the duration of the trialXx_NEWLINE_xXPatients at reproductive potential must agree to practice an effective contraceptive method. Women of childbearing potential must not be pregnant or lactatingXx_NEWLINE_xXWomen who are pregnant or breastfeeding or adults of reproductive potential not employing an adequate method of contraception\r\n* Childbearing potential is defined as: participants who have not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause) and have not undergone surgical sterilization (removal of ovaries and/or uterus)Xx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment armXx_NEWLINE_xXPatients who are pregnant or nursing; if patients are of reproductive age and have not undergone hysterectomy, they must use an effective contraceptive method for the duration of this studyXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method during protocol treatment and up to 8 weeks after ending protocol treatment; a woman is considered to be of “reproductive potential” if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, “effective contraception” also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXWomen of child-bearing potential and men must use an acceptable method of contraception during treatment and for 23 weeks after treatment for women and 31 weeks for menXx_NEWLINE_xXFemales of childbearing potential and nonsterilized males who are sexually active must use effective methods of contraceptionXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method for up to 3 months after the final administered dose of chemotherapy; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXWomen of child-bearing potential (defined as all women physiologically capable of becoming pregnant) and all male participants, unless they are using highly effective methods of contraception for a period of 1 year after the CTL019 infusion.Xx_NEWLINE_xXWomen of childbearing potential and male participants must practice adequate contraceptionXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXPatients of childbearing potential must have a negative pregnancy test within 28 days prior to registration and must not be nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method during the study and for 6 months following completion of treatment; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 90 days after the last dose of atezolizumab or 18 months after the last dose of obinutuzumab, whichever is longerXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of “reproductive potential” if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, “effective contraception” also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXWomen of childbearing potential and sexually active males must agree to practice abstinence or use an accepted and effective method of contraceptionXx_NEWLINE_xXFor women of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use two effective forms of contraceptive methods including at least one that results in a failure rate of less than (<) 1 percent (%) per year during the treatment period and for at least 6 months after the last dose of study drugXx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent or use contraceptive methodsXx_NEWLINE_xXNon-pregnant and not nursing; men and women of childbearing potential must agree to employ adequate contraception for the duration of chemotherapy and for as many as 8 weeks after the completion of chemotherapyXx_NEWLINE_xXWomen of reproductive potential must have a negative pregnancy test within 14 days prior to registration; patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive methodXx_NEWLINE_xXAgreement of women of childbearing potential to use highly effective contraception during receipt of study drug and up to 161 days (23 weeks) from the last dose of nivolumab/placebo and men receiving nivolumab/placebo who are sexually active with women of childbearing potential to use highly effective contraception during receipt of study drug for 31 weeks from the last dose of nivolumab/placebo.Xx_NEWLINE_xXPregnancy, nursing females or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.Xx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of <1% per year, for at least 28 days prior to Day 1 of Cycle 1, during the treatment period (including periods of treatment interruption), and for at least 18 months after the last dose of study treatmentXx_NEWLINE_xXWomen and men of child producing potential must agree to use effective contraceptive methods prior to study entry, during study participation, and for at least 30 days after the last administration of study medication. A serum pregnancy test within 72 hours prior to the initiation of therapy will be required for women of childbearing potential.Xx_NEWLINE_xXWomen of child-bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for 3 months thereafterXx_NEWLINE_xXWomen of childbearing potential and male participants who are unwilling or unable to use an acceptable method of contraception throughout the study and for four weeks after completion of treatment or those who are using a prohibited contraceptive methodXx_NEWLINE_xXPregnant women or sexually active patients not willing or able to use medically acceptable forms of contraceptive method while on treatment.Xx_NEWLINE_xXFertile men and women unwilling to use contraceptive techniques during and for 12 months following treatmentXx_NEWLINE_xXMen and women of childbearing age and potential, who are not willing to use effective contraceptionXx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of study treatmentXx_NEWLINE_xXWomen who are pregnant or breast feeding. Fertile patients (men and women) who are not using an effective method of contraception. All patients (men and women) must agree to use an effective contraceptive measure (if applicable) up to six months after treatment discontinuation.Xx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraceptionXx_NEWLINE_xXAgreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods among women of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study and for at least 3 months after the last dose of ipilimumab in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXmen and women must agree to the use an effective method of contraception during the study and for at least 3 months post last dose of study drug administration. Women of child-bearing potential must have negative serum and urine pregnancy tests at screening and during each treatment cycle, respectivelyXx_NEWLINE_xXFertile men and women must agree to take adequate contraceptive precautions during, and for at least six months after therapyXx_NEWLINE_xXPatients who are pregnant or nursing; women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug; WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IV/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab or nivolumab + ipilimumab; women must not be breastfeeding; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) do not require contraception; women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy and/or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 month amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level greater than 40 mIU/mL; if, following initiation of the investigational product(s), it is subsequently discovered that a study subject is pregnant or may have been pregnant at the time of investigational product exposure, including during at least 6 half-lives after product administration, the investigational product will be permanently discontinued in an appropriate manner (e.g., dose tapering if necessary for subject safety); the investigator must report this event and any outcomes by amendment through Cancer Therapy Evaluation Program (CTEP)-Adverse Event Reporting System (AERS); protocol-required procedures for study discontinuation and follow-up must be performed on the subject unless contraindicated by pregnancy (e.g., X-ray studies); other appropriate pregnancy follow-up procedures should be considered if indicated; in addition, the investigator must report and follow-up on information regarding the course of the pregnancy, including perinatal and neonatal outcome; infants should be followed for a minimum of 8 weeksXx_NEWLINE_xXFor men: agreement to remain abstinent or use a condom plus an additional contraceptive method as specified in protocolXx_NEWLINE_xXWomen of childbearing potential and sexually active males must use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the studyXx_NEWLINE_xXParticipants of childbearing potential must be surgically sterile or consent to use a highly effective method of contraception throughout the study period. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing). If a participant of childbearing potential is neither surgically sterile nor postmenopausal, highly effective contraceptive measures must start either prior to or at Screening and continue throughout the entire study period and for at least 6 months after the last dose of chemotherapy and at least 30 days after the last dose of Test Article (amatuximab or placebo) is administered (whichever is later). A highly effective method of contraception is defined as one that results in a low failure rate (ie, less than 1% per year) when used consistently and correctly. Periodic abstinence, the rhythm method, the withdrawal method, condoms, and diaphragms are not acceptable methods of contraception. Women of childbearing potential must also refrain from egg cell donation for 6 months after the final dose of investigational product.Xx_NEWLINE_xXWomen of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatmentXx_NEWLINE_xXAll men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertileXx_NEWLINE_xXWomen of child bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for 3 months thereafterXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the last dose of investigational product; men on study also must be using contraceptionXx_NEWLINE_xXWomen of childbearing potential and men must be using an acceptable method as described in the protocol to prevent pregnancy.Xx_NEWLINE_xXPregnancy or women of childbearing potential not willing/able to use medically acceptable forms of contraception during protocol treatment or for at least 6 months following treatmentXx_NEWLINE_xXWomen of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 week after completion of dosing.Xx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method while on study and for at least 60 days after study treatment; a woman is considered to be of “reproductive potential” if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, “effective contraception” also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days from day 1 of study drug; both men and women must be willing to use two methods of contraception, one of them being a barrier method during the study and for 4 months after last study drug administrationXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraceptionXx_NEWLINE_xXMen and women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study and for at least 12 weeks after the last dose of investigational product in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXMen of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafterXx_NEWLINE_xXWomen of childbearing potential and sexually active males are strongly advised to use appropriate contraceptive measuresXx_NEWLINE_xXWomen of childbearing potential must be non-pregnant and non-lactating and willing to use medically acceptable form of contraception during radiation therapyXx_NEWLINE_xXMen or women of reproductive ability who are unwilling to use effective contraception or abstinence for 4 months after treatmentXx_NEWLINE_xXPregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within 14 days prior to entry; patients of both genders must practice birth control during treatment and for four months after treatmentXx_NEWLINE_xXMen and women of childbearing potential and their partners must agree to use adequate contraception while enrolled on this study; based on the established teratogenic potential of alkylating agents, pregnant women will be excluded from this study; female patients who are lactating must agree to stop breastfeeding or will otherwise be excluded from this study; females of childbearing potential must have a negative pregnancy test to be eligible for this studyXx_NEWLINE_xXMen of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafterXx_NEWLINE_xXWomen of childbearing potential must be willing to implement adequate contraception during the study. An adequate method of contraception will be at the investigator's discretion.Xx_NEWLINE_xXFertile men and women unwilling to use contraceptives during and for 12 months post-transplantXx_NEWLINE_xXWomen of childbearing potential not using a medically acceptable means of contraceptionXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraceptionXx_NEWLINE_xXSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participationXx_NEWLINE_xXWomen of childbearing potential and males must be willing to use an effective method of contraception from the time consent is signed until 4 weeks after treatment discontinuation.Xx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXMales and females of reproductive potential are not eligible unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXMen who are sexually active with a woman of child-bearing potential and not willing/able to use medically acceptable forms of contraception (e.g., surgical, barrier, medicinal) during protocol treatment and during the first 3 months after cessation of protocol treatmentXx_NEWLINE_xXFemales of reproductive potential must not be pregnant or lactating; males or females of  reproductive potential may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXWomen of childbearing potential must implement adequate contraception in the opinion of the investigatorXx_NEWLINE_xXMen who are sexually active with women of child bearing potential must agree to use a condom from screening through 7 months after the last dose of study treatment (including nivolumab single agent).Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) and men must agree to use effective contraceptive methods from Screening throughout the study treatment period and until at least 90 days after the last dose of IMO-2125, 3 months after the last dose of ipilimumab or at least 4 months after the last dose of pembrolizumab.Xx_NEWLINE_xXWomen of childbearing potential must use effective contraceptionXx_NEWLINE_xXContraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studiesXx_NEWLINE_xXPregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception. Women of childbearing potential with a positive pregnancy test within 3 days prior to pheresis.Xx_NEWLINE_xXPregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception. Women of childbearing potential with a positive pregnancy test within 3 days prior to entry.Xx_NEWLINE_xXFor men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:\r\n* With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of rituximab; men must refrain from donating sperm during this same period\r\n* With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to avoid exposing the embryo\r\n* The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraceptionXx_NEWLINE_xXWomen of childbearing potential (not postmenopausal for at least one year or not surgically incapable of bearing children) must agree not to become pregnant for the duration of the study; both men and women must agree to use a barrier method of contraception for the duration of the study and until 10 weeks after the final dose of UC-961 (expected to be greater than 5 half-lives from pre-clinical data)Xx_NEWLINE_xXWomen and men of reproductive potential should agree to use two effective means of birth control\r\n* For women, contraception should continue for 23 weeks after the last dose of nivolumab and 12 weeks after the last dose of dasatinib to allow complete clearance of drug and its principal metabolites from the body\r\n* For men, contraception should continue for 31 weeks after nivolumab and 12 weeks after dasatinibXx_NEWLINE_xXWomen of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 3 months after treatment completionXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participationXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive methodXx_NEWLINE_xXWomen of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months following last treatmentXx_NEWLINE_xXWomen who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile and azoospermic men do not require contraceptionXx_NEWLINE_xXPatients who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXPatients of childbearing potential, not practicing adequate contraception, patients who are pregnant, or patients who are breastfeeding are not eligible for this trial.Xx_NEWLINE_xXPregnancy and breast feeding\r\n* Female patients who are pregnant; a pregnancy test is required for female patients of childbearing potential\r\n* Lactating females who plan to breastfeed their infants while on study therapy and through 5 months after completion of study therapy\r\n* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for 5 months after the end of study treatmentXx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; the investigator shall review contraception methods and the time period that contraception must be followed; men that are sexually active with WOCBP must follow instructions for birth control for a period of 90 days plus the time required for the investigational drug to undergo 5 half-lives (60 days)Xx_NEWLINE_xXMen or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative urine pregnancy test within 2 weeks prior to first infusionXx_NEWLINE_xXSexually active participants (men and women) must agree to use highly effective contraceptive methods during the course of the study and for 6 months after completing treatment with radium-223Xx_NEWLINE_xXAny of the following:\r\n* Pregnant women\r\n* Nursing women\r\n* Men or women of childbearing potential who are unwilling to employ adequate contraception\r\n** NOTE: men and women of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associateXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXFemale subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraceptionXx_NEWLINE_xXAny of the following:\r\n* Pregnant women \r\n* Nursing women\r\n* Men or women of childbearing potential who are unwilling to employ adequate contraception\r\nNOTE: breastfeeding should be discontinued if the mother is treated with nivolumab; women of childbearing potential and men must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; they must adhere to contraception for a period of 31 weeks after the last dose of nivolumabXx_NEWLINE_xXFor men: Compliant with a medically-approved contraceptive regimen during and for 3 months after the treatment period or documented to be surgically sterile. Men whose sexual partners are of child-bearing potential must agree to use a medically-approved contraceptive regimen during the study and for 3 months after the treatment period.Xx_NEWLINE_xXWomen of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab; women must not be breastfeeding; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraceptionXx_NEWLINE_xXFor women of childbearing potential, agreement to refrain from heterosexual intercourse or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab, 3 months after the last dose of vinflunine and 6 months from the last dose of paclitaxel or docetaxel.Xx_NEWLINE_xXMen and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for males at least 4 months thereafter, and for females at least 3 months thereafterXx_NEWLINE_xXMen and women of childbearing potential must agree to use adequate contraception from the time of consent through 30 days after final study treatment.Xx_NEWLINE_xXWomen of childbearing potential (WOCBP), or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trial and for at least three months after the end of active therapyXx_NEWLINE_xXEffective contraception is required while receiving GA101 - obinutuzumab; for women of childbearing potential and men, effective contraception is required while receiving GA101 – obinutuzumab and for 365 days (12 months) after the last dose of the study drugXx_NEWLINE_xXAny of the following:\r\n* Pregnant women\r\n* Nursing women\r\n* Men and women of reproductive potential who are not using effective birth control methods\r\nNote: women of childbearing potential must have a negative serum pregnancy test =< 7 days prior to registration/randomization; adequate contraception must be used while receiving study drug and for 12 weeks after the last dose of study drug, by both women and men and by both patient and partner; men who have a partner of childbearing potential should also avoid fathering a child for 6 months after the last dose of study drugXx_NEWLINE_xXMen must be willing to use appropriate contraception throughout study and for 6 months after; women must be willing to use appropriate contraception throughout study and for 20 months afterXx_NEWLINE_xXWomen with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent; adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinenceXx_NEWLINE_xXPregnant or breast-feeding women and women of childbearing age or men who are unwilling to use adequate contraception; females of childbearing age and potential (i.e., not surgically sterilized) must use a second form of contraception, including total abstinence, intra-uterine device, double-barrier contraception, or other non-hormonal form of contraceptionXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for 90 days after the last dose of study drugXx_NEWLINE_xXPregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception; women of childbearing potential with a positive pregnancy test within 3 days prior to entryXx_NEWLINE_xXCOHORT A: Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study (and for up to 26 weeks after the last dose of ipilimumab) in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXCOHORT A: Persons of reproductive potential unwilling to use an adequate method of contraception throughout treatment and for at least 26 weeks after ipilimumab is stoppedXx_NEWLINE_xXCOHORT B: Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study (and for up to 26 weeks after the last dose of ipilimumab) in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXCOHORT B: Persons of reproductive potential unwilling to use an adequate method of contraception throughout treatment and for at least 26 weeks after ipilimumab is stoppedXx_NEWLINE_xXPatients must be willing to use contraception if they have childbearing potentialXx_NEWLINE_xXWomen of childbearing potential and men who participate in the study must agree to use adequate contraception (hormonal or barrier methods) before, during the study and for a period of 3 months after the last dose of chemotherapyXx_NEWLINE_xXFertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative pregnancy test ? 72 hours prior to Day 1 of study.Xx_NEWLINE_xXMen and women of childbearing potential must be willing to us two highly effective forms of contraception while on treatment and for at least 3 months after last dose of study drug.Xx_NEWLINE_xXPatient at reproductive potential must agree to practice an effective contraceptive method.Xx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinentXx_NEWLINE_xXSexually active men and their sexual partners must use effective contraceptive methods from the time of participant informed consent and until at least 3 months after discontinuing study drugXx_NEWLINE_xXFor men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:\r\n* With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of rituximab; men must refrain from donating sperm during this same period\r\n* With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to avoid exposing the embryo\r\n* The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraceptionXx_NEWLINE_xXMen must practice effective contraceptive methods during the study, unless documentation of infertility existsXx_NEWLINE_xXMen unwilling to practice contraceptive methods during the study periodXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; hormonal contraception is not allowed; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXWomen of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraceptionXx_NEWLINE_xXMen of child bearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafterXx_NEWLINE_xXMen and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months after treatmentXx_NEWLINE_xXWomen of childbearing potential and men with partners of childbearing potential must be willing to use one highly effective form on nonhormonal contraception or two effective forms of nonhormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for 7 months after the last dose of study treatmentXx_NEWLINE_xXAny of the following:\r\n* Pregnant women\r\n* Nursing women\r\n* Women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragms, intrauterine devices [IUDS], surgical sterilization, abstinence, etc); hormonal birth control methods are not permitted\r\n* Men who are unwilling to employ adequate contraception (condoms, surgical sterilization, abstinence, etc)Xx_NEWLINE_xXAny of the following:\r\n* Pregnant women or women of reproductive capability who are unwilling to use effective contraception\r\n* Nursing women\r\n* Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 28 days after stopping treatmentXx_NEWLINE_xXFertile men must practice effective contraceptive methods during the study, unless documentation of infertility existsXx_NEWLINE_xXFertile men unwilling to practice contraceptive methods during the study periodXx_NEWLINE_xXFertile men must practice effective contraceptive methods during the study, unless documentation of infertility existsXx_NEWLINE_xXFertile men unwilling to practice contraceptive methods during the study periodXx_NEWLINE_xXMen and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafterXx_NEWLINE_xXSubjects must not be pregnant or breastfeeding; pregnancy tests must be obtained for all females of child-bearing potential; pregnant or lactating patients are ineligible for this study; males or females of reproductive age may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXFertile women of childbearing potential (WCBP) not using (or refusing to use) adequate methods of contraception as agreed on between her and the consenting investigator; male participants not using (or refusing to use) a condom during intercourseXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception .Xx_NEWLINE_xXFor women who are not postmenopausal or surgically sterile: agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 7 months after the last dose of study drugXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential must commit to the use of effective barrier (non-hormonal) contraception while on studyXx_NEWLINE_xXFor women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenibXx_NEWLINE_xXPregnant or breast feeding women, or women and men of childbearing potential not willing to use adequate contraception while on treatment and for at least 3 months thereafterXx_NEWLINE_xXWomen of childbearing potential and sexually active men must agree to use effective contraception prior to study entry, for the duration of study participation and for three months after completing treatment; adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of careXx_NEWLINE_xXPatient must not be pregnant or breastfeeding; if a woman of childbearing potential, patient must agree to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen with child bearing potential and men with reproductive potential must be willing to practice acceptable methods of contraceptionXx_NEWLINE_xXWomen of childbearing potential and male participants must use an effective contraception method; (until at least 60 days following treatment)Xx_NEWLINE_xXPregnant or lactating women or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after the last dose of study drugXx_NEWLINE_xXAll males and females of childbearing potential must agree to use adequate contraception during the study; adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomyXx_NEWLINE_xXPregnant or lactating women, or adults of reproductive potential who do not agree to use adequate contraception during study treatmentXx_NEWLINE_xXWomen of childbearing potential and men must agree to use effective contraceptive methods while on study and for at least twelve weeks after the last dose of study drug.Xx_NEWLINE_xXMales and females of reproductive potential must agree to use an effective contraceptive method during the treatment, and after the end of treatment: during twelve months for women, taking into account the characteristics of rituximab and during five months for men, taking into account the characteristics of methotrexateXx_NEWLINE_xXFemales of childbearing potential, and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 6 months following the last dose of brentuximab vedotin; effective contraception is defined as any medically recommended method (or combination of methods) as per standard of care, including abstinence; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomyXx_NEWLINE_xXMale patients of child fathering potential are not eligible unless they have agreed to use latex condoms during intercourse with a woman of childbearing potential while receiving treatment and for 28 days thereafterXx_NEWLINE_xXMale patient whose sexual partner(s) are women of childbearing potential (WOCBP) who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXWomen of childbearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment with 5-azacitidine; all men and women of childbearing potential must use acceptable methods of birth control throughout the studyXx_NEWLINE_xXMales and females of reproductive potential must agree to use an effective contraceptive method during the treatment, and after the end of treatment: during twelve months for women, taking into account the characteristics of rituximab and during five months for men, taking into account the characteristics of methotrexate.Xx_NEWLINE_xXMen of fathering potential must be using an adequate method of contraception to avoid conception throughout the study (and for up to 26 weeks after the last dose of investigational product) in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXWomen of childbearing potential (WOCBP) and men who are sexually active, even if surgically sterilized, with WOCBP must agree to use effective methods of contraception during active treatment, for the duration of the study, and for 3 months after the completion of the studyXx_NEWLINE_xXWomen of childbearing potential must be non-pregnant (negative pregnancy test within 72 hours prior to radiation simulation, postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential) and nonlactating, and men and women must be willing to exercise an effective form of birth control (abstinence/contraception) while on study and for 3 months after therapy completedXx_NEWLINE_xXWomen of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended.Xx_NEWLINE_xXMen of fathering potential must be using an adequate method of contraception to avoid conception throughout the study (and for up to 26 weeks after the last dose of investigational product) in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXFemales of childbearing potential, and males, must be willing to use an effective method of contraceptionXx_NEWLINE_xXMen of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafterXx_NEWLINE_xXPregnant or lactating women; women and men of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finishedXx_NEWLINE_xXAny of the following:\r\n* Pregnant women or women of reproductive ability who are unwilling to use 2 effective methods of contraception from the time of signing the informed consent form through 90 days after the last dose of study drug\r\n* Nursing women\r\n* Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 30 days after stopping treatmentXx_NEWLINE_xXWomen of childbearing potential and male participants must practice adequate contraceptionXx_NEWLINE_xXFertile men or women unwilling to use contraceptive techniques from the time of initiation of mobilization until six-months post-transplant.Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) should be willing to use 2 forms of contraception; male patients should be willing to use contraceptionXx_NEWLINE_xXUse of effective contraceptive methods if men and women of child producing potentialXx_NEWLINE_xXFertile men and women unwilling to use contraceptives during and for 12 months post-transplantXx_NEWLINE_xXWomen of child-bearing potential and sexually active men must agree to use adequate contraception prior to study entry for six months following duration of study participationXx_NEWLINE_xXWomen who are pregnant or breast feeding, or women/men of reproductive potential who are not using and unwilling to practice an effective method of birth control; (women of childbearing potential must have a negative serum pregnancy test within 7 days prior to administration of pasireotide and RAD001)Xx_NEWLINE_xXMale patient whose sexual partner(s) are women of childbearing potential (WOCBP) who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXPregnant women or women of reproductive ability who are unwilling to use effective contraception during the study and for 3 months after stopping treatmentXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraceptionXx_NEWLINE_xXFertile men or women unwilling to use contraceptive techniques during and for 12 months following treatmentXx_NEWLINE_xXWomen must not be pregnant or nursing at the time of radical cystectomy; women of reproductive potential must agree to use an effective contraceptive method at the time of radical cystectomy, throughout the surgical recovery period, and during post-operative neoadjuvant chemotherapy (if clinically indicated); a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, she is responsible for beginning contraceptive measuresXx_NEWLINE_xXSexually active patients of reproductive potential must be willing to use an effective method of contraceptionXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) must use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; women who are not of childbearing potential are not required to use contraceptionXx_NEWLINE_xXMen who are sexually active with women of child bearing potential must use adequate contraception upon study entry until 31 weeks after the last dose of study treatment; men who are surgically sterile or azoospermic do not require contraceptionXx_NEWLINE_xXWomen of reproductive potential must have a negative blood pregnancy test and agree to use highly effective contraceptive methods.Xx_NEWLINE_xXFertile men and women of childbearing potential must agree to use an effective method of birth control from Day 1 of study and for 120 days after last pembrolizumab administration in both sexes. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative pregnancy test ? 72 hours prior to Day 1 of study.Xx_NEWLINE_xXWomen of childbearing potential and men must agree to use effective contraceptive methods from Screening throughout the study treatment period and until at least 4 weeks after the last dose of study drug.Xx_NEWLINE_xXStated willingness to use contraception in women of childbearing potential.Xx_NEWLINE_xXPatients who are pregnant (positive pregnancy test) or nursing. Use of effective means of contraception (men and women) in subjects of child-bearing potential. To date, no fetal studies in animals or humans have been performed. The possibility of harm to a fetus is likely. Bevacizumab specifically inhibits VEGF, which is responsible for formation of new blood vessels during development, and antibodies can cross the placenta. Therefore, bevacizumab should not be administered to pregnant women.Xx_NEWLINE_xXUse of effective contraceptive methods if men and women of child producing potentialXx_NEWLINE_xXWomen of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraceptionXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use an accepted method of contraceptionXx_NEWLINE_xXPregnant or nursing women may not participate; women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; pregnancy test required for women of childbearing potentialXx_NEWLINE_xXFertile men and women unwilling to use contraceptives during and for 12 months post-transplantXx_NEWLINE_xXPregnant or lactating; patients of childbearing potential must use an effective method of contraceptionXx_NEWLINE_xXMen and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafterXx_NEWLINE_xXAny of the following:\r\n* Pregnant women or women of reproductive ability who are unwilling to use effective contraception\r\n* Nursing women \r\n* Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatmentXx_NEWLINE_xXSubjects who are pregnant, lactating, or of reproductive potential and not practicing an effective means of contraceptionXx_NEWLINE_xXPregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control.Xx_NEWLINE_xXThe study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib/GSK2141795, the potential hazard to the fetus should be explained to the patient and partner (as applicable)Xx_NEWLINE_xXFertile men or women unwilling to use contraceptive techniques during and for 12 months following transplantXx_NEWLINE_xXMen or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks following the completion of study drug treatment.Xx_NEWLINE_xXMales and females of childbearing potential must be able and willing to use an effective contraceptive method during treatment and for three months after completing treatmentXx_NEWLINE_xXWomen of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study and for 30 days following the last dose;Xx_NEWLINE_xXWomen of child bearing potential (WOCBP) and men able to father children who are sexually active with WOCBP must agree to use acceptable contraception\r\n* Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and azoospermic men do not require contraception\r\n* Women of childbearing potential receiving nivolumab will be instructed to use and must be willing to use appropriate method(s) of contraception for a period of 23 weeks after the last dose of investigational product\r\n* Men receiving nivolumab who are sexually active with WOCBP will be instructed to use and must be willing to use acceptable contraception for a period of 31 weeks after the last dose of investigational productXx_NEWLINE_xXWomen of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 45 days after stopping study medication. Highly effective contraception methods include:Xx_NEWLINE_xXIn case of use of oral contraception women should have been stabile on the same pill for a minimum of 3 months before taking study treatment.Xx_NEWLINE_xXPatients must be willing to use contraception if they have childbearing potentialXx_NEWLINE_xXPregnancy, or unwillingness to use contraception if they are have childbearing potentialXx_NEWLINE_xXWilling to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of any study therapy). This applies to women of childbearing potential as well as fertile men and their partnersXx_NEWLINE_xXMen and women agreement to use effective contraceptive method. For WOCBP and for men, agreement to use an effective contraceptive method from the time of screening throughout the study until 1 month for WOCBP or 6 months for men after administration of the last dose of any study medication.Xx_NEWLINE_xXWomen with reproductive capability must be willing to use effective contraceptionXx_NEWLINE_xXUse of effective contraception by women of childbearing potental.Xx_NEWLINE_xXMen and women of childbearing potential should practice effective methods of contraception; men and women of childbearing potential are defined as: a male that has not been surgically sterilized or female that has not been amenorrheic for at least 12 consecutive months or that has not been surgically sterilized; patients must use birth control during the study and for 3 months after the last dose of study drug if they are sexually activeXx_NEWLINE_xXWomen of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 3 months after study drug discontinuation; highly effective methods of contraception are further definedXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXFertile men must practice effective contraceptive methods during the study, unless documentation of infertility existsXx_NEWLINE_xXFertile men unwilling to practice contraceptive methods during the study periodXx_NEWLINE_xXMen of childbearing potential who agree to use contraception prior to study entry and for the duration of participationXx_NEWLINE_xXWomen of childbearing potential (WOCBP) and men who are sexually active with WOCBP must agree to use effective methods of contraception during active treatment and for the duration of the studyXx_NEWLINE_xXMales or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method from the time of study entry to a period of no less than four months post the HSV1716 injectionXx_NEWLINE_xXMen not willing to use an effective contraception method while on studyXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential not using a medically acceptable means of contraception for the duration of the study.Xx_NEWLINE_xXAny of the following:\r\n* Pregnant women\r\n* Nursing women\r\n* Women of childbearing potential who are unwilling to employ adequate contraception\r\n* NOTE: breastfeeding should be discontinued if the mother is treated with MK-2206; women of childbearing potential must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participationXx_NEWLINE_xXPregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to entryXx_NEWLINE_xXWomen of childbearing age must be on effective contraceptionXx_NEWLINE_xXWomen of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study is potentially teratogenicXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding women should be excluded; women of childbearing potential and men must agree to use adequate contraception (barrier methods) before, during the study and for a period of 3 months after the last dose of the investigational agentXx_NEWLINE_xXWomen (of childbearing potential) and men who are sexually active and are not willing/able to use a medically acceptable form of contraception throughout the treatment and 60 days thereafterXx_NEWLINE_xXMen of childbearing potential must consent to use barrier contraception while on treatment and for 90 days thereafterXx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 5 months after the last dose of study drugXx_NEWLINE_xXAdult men and womenXx_NEWLINE_xXWomen of childbearing potential must agree to follow instruction for method(s) of contraception from time of enrollment for the duration of treatment with nivolumab plus 5 half-lives plus 30 days for a total of 23 weeks post treatment completionXx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate if less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational productXx_NEWLINE_xXWomen who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraceptionXx_NEWLINE_xXAzoospermic males and women of childbearing potential who are continuously not heterosexually active are exempt from contraceptive requirements; however, they still must have a pregnancy testXx_NEWLINE_xXFor women of childbearing potential and men, agree to use effective contraceptive methods from screening, through the study, and for at least 4 weeks after the last dose of study drug.Xx_NEWLINE_xXWomen of childbearing potential and sexually active men enrolled in the study must agree to practice effective contraception method during treatment and for three months after completing treatmentXx_NEWLINE_xXSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 23 or 31 weeks for women or men respectively, after the last dose of study drugs, even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 23 or 31 weeks for women and men respectively after the last dose of study drugsXx_NEWLINE_xXWomen of reproductive potential must agree to use an effective non-hormonal method of contraception during therapyXx_NEWLINE_xXFor men and women of child-producing potential, use of effective barrier contraceptive methods during the study and for one month following study product injectionsXx_NEWLINE_xXMen or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception.Xx_NEWLINE_xXWomen of child-bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for 3 months thereafterXx_NEWLINE_xXPersons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 5 months after ipilimumab/nivolumab is stopped (7 months for men)\r\n* Sexually active WOCBP must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; all WOCBP MUST have a negative pregnancy test before first receiving ipilimumab/nivolumab; if the pregnancy test is positive, the patient must not receive ipilimumab/nivolumab and must not be enrolled in the studyXx_NEWLINE_xXFor women of childbearing potential, agreement to use two effective forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drugXx_NEWLINE_xXMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraceptionXx_NEWLINE_xXFor women of childbearing potential, agreement to use two effective forms of contraceptionXx_NEWLINE_xXFemale patients of childbearing potential who are sexually active and unwilling to use a medically acceptable method of contraception during the trial and for 6 months after the last administration of BI 836858Xx_NEWLINE_xXFemales of childbearing potential and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 6 months following the last dose of brentuximab vedotin or 12 months following the last dose of rituximab, whichever is later.Xx_NEWLINE_xXSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for 2 months after the end of study treatmentXx_NEWLINE_xXFor women of childbearing potential and men with partners of childbearing potential, agreement to use two effective forms of contraceptionXx_NEWLINE_xXFor women of childbearing potential and men with partners of childbearing potential, agreement to use two effective forms of contraceptionXx_NEWLINE_xXWomen who are pregnant or breastfeeding, or women of childbearing potential without using dual forms of effective contraceptionXx_NEWLINE_xXMen or pre-menopausal women who are not using an effective method of contraception as previously described; actively breast feeding women.Xx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXWomen of childbearing potential and men with female sexual partners of childbearing potential must agree to abstain from sexual intercourse or use a double barrier method to determine if a woman is of childbearing potential (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp).Xx_NEWLINE_xXFor men and women of childbearing potential, willingness to abstain from sexual intercourse or employ an effective method of contraception during the study drug administration and follow-up periodsXx_NEWLINE_xXWomen of childbearing potential and men should agree to use an effective form of contraception and to continue its use for the duration of study treatment and for a period of time after the last dose of study treatmentXx_NEWLINE_xXFor women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least 6 months after the termination visit.Xx_NEWLINE_xXSexually active women of childbearing potential must commit to 2 methods of contraception while enrolled on the trial and continue using contraceptives for at least 7 months post study drug administration; sexually active men must commit to 1 method of contraception while enrolled and for 7 months after; hormonal contraceptives such as birth control pills, patches, implants or injections are not allowed in patients who are hormone receptor (HR) positive (+)Xx_NEWLINE_xXWomen of childbearing potential must be willing to use a highly effective form of contraception for the duration of the trial and for 18 weeks (5 half-lives) after the last dose of treatmentXx_NEWLINE_xXMen and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafterXx_NEWLINE_xXPregnant or nursing females; any patient of reproductive potential may not participate unless he/she has agreed to use an effective contraceptive method as covered during the informed consent processXx_NEWLINE_xXFor women of childbearing potential, agreement to use two effective forms of contraceptionXx_NEWLINE_xXPatients with reproductive potential must use contraceptive methodsXx_NEWLINE_xXWomen of childbearing potential and sexually active men must agree to use effective contraception prior to study entry, for the duration of study participation and for three months after completing treatment; adequate contraception is defined as any medically recommended method (or combination of methods) per standard of careXx_NEWLINE_xXAll men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile.Xx_NEWLINE_xXPregnancy, or inadequate contraception for men or women of childbearing age, or lactating / breast-feedingXx_NEWLINE_xXPatients of childbearing potential who are sexually active and unwilling to use a highly effective method of contraceptionXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXWomen of childbearing potential (WOCBP) and men must use highly effective methods of contraceptionXx_NEWLINE_xXFor women of childbearing potential and men with partners of childbearing potential, agreement to use two effective forms of contraceptionXx_NEWLINE_xXWomen of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study for 60 days after study drug discontinuationXx_NEWLINE_xXThe study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)Xx_NEWLINE_xXFor women of childbearing potential, agreement to use two effective forms of contraceptionXx_NEWLINE_xXFor women of childbearing potential and men with partners of childbearing potential, agreement to use two effective forms of contraceptionXx_NEWLINE_xXThe following patients will be excluded from this study:\r\n* Pregnant women\r\n* Breastfeeding women\r\n* Men or women who are sexually active and unwilling to use a medically acceptable method of contraception (e.g., such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner for participating females, condoms for participating males) during the trial and for at least 6 months after end of active therapy; a highly effective method of birth control is defined as one which results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly; patients will be considered to be of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation/salpingectomy, or post-menopausal for at least 2 yearsXx_NEWLINE_xXWomen of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatmentXx_NEWLINE_xXWomen of childbearing potential must be willing to avoid pregnancy by using an adequate method of contraception for 2 weeks prior to screening, during and at least 3 months after the last dose of trial medication.Xx_NEWLINE_xXFor men and women of child-producing potential - willingness to employ appropriate contraceptive methods (including abstinence) during the study.Xx_NEWLINE_xXWomen of childbearing potential must agree to use contraception as defined by protocol during treatment and for at least 9 months after completion of study treatmentXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXAny of the following:\r\n* Pregnant women\r\n* Nursing women (lactating females must agree not to breast feed while taking lenalidomide)\r\n* Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], or abstinence, etc.)Xx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraceptionXx_NEWLINE_xXAny of the following:\r\n* Pregnant women or women of reproductive ability who are unwilling to use 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of study drug\r\n* Nursing women\r\n* Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 30 days after stopping treatmentXx_NEWLINE_xXWomen and men of childbearing potential must be advised and agree to practice effective methods of contraception during the course of the study and for 4 weeks after the last AGS-16C3F infusion administrationXx_NEWLINE_xXAny of the following:\r\n* Pregnant women or women of reproductive ability who are unwilling to use effective contraception\r\n* Nursing women - NOTE: breastfeeding should be discontinued if the mother is treated with nab-paclitaxel (Abraxane®)\r\n* Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 28 days after stopping treatmentXx_NEWLINE_xXWomen of child producing potential must agree to use effective contraceptive methods prior to study entry, during study participation, and for at least 30 days after the last administration of study medication. A serum pregnancy test within 72 hours prior to the initiation of therapy will be required for women of childbearing potential.Xx_NEWLINE_xXPregnancy: Serum B-HCG must be negative in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.Xx_NEWLINE_xXCohort A: Men and women of childbearing potential must be willing to use effective contraception while on treatment and for at least 3 months thereafterXx_NEWLINE_xXSexually active patients of reproductive potential must be willing to use an effective method of contraceptionXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to enrollment and must agree to use adequate contraception prior to enrollment and for the duration of study participation; subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 30 days after the last dose of study drugXx_NEWLINE_xXWomen of childbearing potential and male participants must practice adequate contraceptionXx_NEWLINE_xXWomen of childbearing potential must have agreed to use an effective contraceptive method; a woman is considered to be of \childbearing potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, she is responsible for beginning contraceptive measures\r\n* Women of childbearing potential will have a pregnancy test to determine eligibility as part of the pre-study evaluation; this may include an ultrasound to rule-out pregnancy if a false-positive is suspected; patient will be considered eligible if an ultrasound is negative for pregnancyXx_NEWLINE_xXFor women of childbearing potential: agreement to use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 6 weeks after the last dose of idasanutlinXx_NEWLINE_xXInclusion Criteria:\n\n          -  Life expectancy of at least 3 months\n\n          -  Histological or cytological documentation of advanced solid tumors\n\n          -  ECOG Performance Status of ? 1 (ECOG: Eastern Cooperative Oncology Group)\n\n          -  Adequate bone marrow, liver and renal function\n\n          -  Women of childbearing potential and men must agree to use adequate contraceptionXx_NEWLINE_xXWomen of childbearing potential or men with partners of childbearing potential who are not protected or who are unwilling to use an effective contraceptive method of birth control during the course of the study and for a period of 6 months following the last dose.Xx_NEWLINE_xXMale patient whose sexual partner(s) are women of childbearing potential (WOCBP) who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatmentXx_NEWLINE_xXAny of the following:\r\n* Pregnant women\r\n* Nursing women\r\n* Men or women of childbearing potential who are unwilling to employ adequate contraception for the duration of study participation; men and women should continue to use adequate birth control after the last administration of sorafenib and TH-302 under the guidance of their treating physicianXx_NEWLINE_xXSexually active women of childbearing potential must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy; in addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control; all WOCBP MUST have a negative pregnancy test prior to first receiving investigational product; if the pregnancy test is positive, the patient must not receive investigational product and must not be enrolled in the study; in addition, all WOCBP should be instructed to contact the Investigator immediately if they suspect they might be pregnant (e.g., missed or late menstrual period) at any time during study participationXx_NEWLINE_xXWomen of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy throughout the study and for at least 4 weeks prior to initiation of dosing, and for at least 60 days after the last dose of investigational product in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and for a period of 3 months. Female subjects considered not of childbearing potential must be documented as being surgically sterile or post-menopausal for at least 1 year.Xx_NEWLINE_xXMen or women of childbearing potential who are not using an effective method of contraception as previously described; women who are pregnant or breast feeding.Xx_NEWLINE_xXFor fertile men or women of childbearing potential, documented willingness to use a highly effective means of contraceptionXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within 14 days of the administration of the first study treatment; women must not be lactating; both men and women of childbearing potential must be advised of the importance of using effective birth control measures during the course of the study; oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this studyXx_NEWLINE_xXUse of an effective means of contraception (e.g., abstinence, hormonal or double barrier method, surgically sterilized partner) for men and women of childbearing potential while enrolled in the studyXx_NEWLINE_xXPregnant or lactating women are not eligible; women or men of childbearing potential not using a reliable and appropriate contraceptive method are not eligible (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)Xx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenicXx_NEWLINE_xXPregnant women, or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception for the duration of study treatment and for up to 4 weeks following SBRTXx_NEWLINE_xXDONOR: Donors must not be pregnant; donors of childbearing potential must use an effective method of contraception from the time of study entry until at least one year post-transplantXx_NEWLINE_xXA medically accepted method of contraception to be used by women of childbearing potential (not surgically sterile or at least 12 months naturally postmenopausal)Xx_NEWLINE_xXPregnancy or breast feeding: study participants who are pregnant are not eligible for this study; pregnancy tests must be obtained in girls who are > 10 years of age or post-menarchal within 7 days prior to study enrollment; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during participation in the trial; breast feeding should be discontinued if a mother wishes to participate in this studyXx_NEWLINE_xXUse of an effective contraceptive, as specified by protocol; women of childbearing potential cannot be pregnant or breastfeedingXx_NEWLINE_xXWomen of childbearing potential must have a negative serum pregnancy test within two weeks of study entry and should be advised to avoid becoming pregnant; men should be advised to not father a child while on treatment; both women of childbearing potential and men must agree to practice effective methods of contraceptionXx_NEWLINE_xXWilling to abstain from sexual intercourse or to use an effective form of contraception during the study and for 120 days following the last dose of any study therapy). This applies to women of childbearing potential as well as fertile men and their partnersXx_NEWLINE_xXSexually active females of childbearing potential and sexually active males with partners of reproductive potential: unwilling or unable to use appropriate contraception from screening until at least 30 days after last administration of study treatmentXx_NEWLINE_xXAll men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile.Xx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinentXx_NEWLINE_xXMen receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; men who are sexually active with WOCBP must use a contraceptive method with a failure rate of less than 1% per yearXx_NEWLINE_xXWomen of child-bearing potential unless they are using highly effective methods of contraception during the study treatment and for 21 days after stopping the study treatment.Xx_NEWLINE_xXWomen of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatmentXx_NEWLINE_xXWomen of childbearing potential and male participants must practice adequate contraceptionXx_NEWLINE_xXWomen of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must be using an adequate method of contraception.Xx_NEWLINE_xXPatients must not be pregnant or nursing due to potential fetal or nursing infant harm; women/men of reproductive potential must have agreed to use an effective contraceptive method, a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXConcurrent oral contraceptive use / Women of childbearing potential not using highly effective means of contraception;Xx_NEWLINE_xXPatients must not be pregnant or nursing; women of reproductive potential must have a negative serum pregnancy test within 7 days prior to registration; women/men of reproductive potential must have agreed to use an effective contraceptive method while on study and for 120 days after last study treatment; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception.Xx_NEWLINE_xXWomen of childbearing potential must agree to use effective contraceptives (as discussed with their physician) while participating in this studyXx_NEWLINE_xXPregnant or lactating women may not participate; women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXWomen or men of childbearing potential unwilling to take adequate precautions to avoid pregnancy from the start of protocol treatment through 28 days after the last treatmentXx_NEWLINE_xXWomen of childbearing potential should use effective contraception during and for two months after stopping fingolimodXx_NEWLINE_xXSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participationXx_NEWLINE_xXPregnant or lactating women, or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of reproductive capability will be enrolled; contraception is not necessaryXx_NEWLINE_xXAny of the following:\r\n* Pregnant women\r\n* Nursing women\r\n* Men or women of childbearing potential who are unwilling to employ adequate contraception\r\n** Note: women of child bearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 33 days after finishing the last dose\r\n** Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 93 days after finishing the last dose\r\n** Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements; however they must still undergo pregnancy testing as described in this sectionXx_NEWLINE_xXWomen of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatmentXx_NEWLINE_xXPregnant and lactating women; women of reproductive age must be willing to use contraception during study therapyXx_NEWLINE_xXNegative serum pregnancy test in women of childbearing potential within 7 days of first dose of treatment and patients of child-bearing potential must agree to use effective contraception during/after 3 months post dose; a woman of childbearing potential is defined as a premenopausal female capable of becoming pregnant; this includes women on oral, injectable or mechanical contraception; women who are single and women whose male sexual partners have been vasectomized or whose male sexual partners have received or are utilizing mechanical contraceptive devicesXx_NEWLINE_xXWomen of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatmentXx_NEWLINE_xXWomen of childbearing potential (women with regular menses, women with amenorrhea, women with irregular cycles, women using a contraceptive method that precludes withdrawal bleeding, and women who have had a tubal ligation) are required to have a negative urine pregnancy test within 14 days prior to the first dose of lithiumXx_NEWLINE_xXWomen of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study is potentially teratogenicXx_NEWLINE_xXSubjects of reproductive potential who are pregnant, breast feeding or not willing to use effective contraceptive precautions during the study and for at least one month after the last dose of investigational product in the judgment of the investigator (including females of childbearing potential who are partners of male subjects).Xx_NEWLINE_xXPatients (both men and women) with reproductive potential not willing to use an effective method of contraceptionXx_NEWLINE_xXNote:  We are excluding women of childbearing potential as this is a pilot trial and allowing women of childbearing potential with hot flashes to participate would introduce a hormonal heterogeneous population that would confound the ability to answer the research questionXx_NEWLINE_xXGENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Pregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in females who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXWomen who are pregnant or breastfeeding are excluded; patients with reproductive potential must agree to use an effective contraceptive method during treatmentXx_NEWLINE_xXWomen of childbearing potential must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the following year until the year 1 AB-MR and DBT studies are performedXx_NEWLINE_xXPatients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of \reproductive potential\ if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \effective contraception\ also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measuresXx_NEWLINE_xXFor women of childbearing potential; negative pregnancy testing within 72 hours prior to or on study visit #1 (day 0) and willingness to use adequate contraception during the study intervention; OR post-menopausal defined as any one of the following 1) prior hysterectomy, 2) absence of menstrual period for 1 year in the absence of prior chemotherapy or 3) absence of menstrual period for 2 years in women with a prior history of chemotherapy exposure who were pre-menopausal prior to chemotherapy; in women of childbearing potential, effective contraception must be used for one month prior to the initiation of therapy, during therapy, and for at least one month following discontinuation of therapy; it is recommended that two reliable forms of contraception be used simultaneously; If participants are interested in enrolling and have not met the requirement for contraception, they will be seen in the clinic in 1 month for re-evaluation once they have met this requirement and ensure all other eligibility criteria is met prior to dose assignmentXx_NEWLINE_xXIf the participant is of childbearing potential, she should be at least 3 months postpartumXx_NEWLINE_xXFor women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception; for men: agreement to use a barrier method of contraception during the treatment periodXx_NEWLINE_xXPregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXFertile men or women unwilling to use contraception during HCT and for 12 months afterwardXx_NEWLINE_xXMen or women of childbearing potential who are unwilling to employ adequate contraceptionXx_NEWLINE_xXWomen of childbearing potential not using the contraception method(s), as well as women who are breastfeedingXx_NEWLINE_xXWomen of child-bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for 3 months thereafterXx_NEWLINE_xXPregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)Xx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 5 months after the last dose of study treatmentXx_NEWLINE_xXWomen of childbearing potential must commit to either abstain continuously from heterosexual sexual intercourse or to use highly effective method of contraceptionXx_NEWLINE_xXPregnant, breastfeeding, or women of childbearing potential unwilling to use a reliable contraceptive methodXx_NEWLINE_xXWomen of childbearing potential and sexually active males must use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the studyXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must not be pregnantXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXFor participants of childbearing potential, not pregnant, and use of effective contraceptive methods during the trial and within 6 months following radiotracer injectionXx_NEWLINE_xXMen of reproductive potential must use condomsXx_NEWLINE_xXWomen of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraceptionXx_NEWLINE_xXPregnant women are excluded from this study because chemoradiotherapy has the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to the use of ferumoxytol as a contrast agent in the mother, breastfeeding should be discontinued if the mother receives ferumoxytol while nursing; men who are sexually active and not willing/able to use medically acceptable forms of contraception are also excluded from this studyXx_NEWLINE_xXSexually active patients of childbearing potential not using a reliable contraceptive methodXx_NEWLINE_xXWomen of childbearing potential must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the studyXx_NEWLINE_xXWomen of childbearing potential (WOCBP) and men who refuse to comply with appropriate contraceptionXx_NEWLINE_xXWomen who are pregnant or breast-feeding; female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy; a negative pregnancy test is required within 24 hours of administration of radiotracer and study initiation for women of childbearing age and potentialXx_NEWLINE_xXwomen of childbearing potential, or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trialXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraceptionXx_NEWLINE_xXWomen of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the studyXx_NEWLINE_xXFor men of childbearing potential, the use of effective contraceptive methods during the trial and within 6 months following radiotracer injectionXx_NEWLINE_xXPregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to entryXx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (<) 1% per year during the treatment period and for at least 5 months after the last dose of study drugsXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must be willing to use an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimizedXx_NEWLINE_xXWomen of childbearing potential must be non-pregnant and non-lactating and willing to use medically acceptable form of contraception during radiation therapyXx_NEWLINE_xXPregnant or nursing women will not participate; women of reproductive potential must be offered a pre-treatment pregnancy test and informed of the need to practice an effective contraceptive method during the therapyXx_NEWLINE_xXMen or women of childbearing potential who are not using an effective method of contraception as previously described; women who are pregnant or breast feeding.Xx_NEWLINE_xXMen and women, ages ?18Xx_NEWLINE_xXWomen of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study and for 14 days after the final dose of nilotinib. Highly effective contraception is defined as either:Xx_NEWLINE_xXWomen of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of treatment on the study; women must not be breastfeeding; men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab +/- ipilimumab and blinatumomab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception\r\n* Note: women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL\r\n* Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediatelyXx_NEWLINE_xXFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of carboplatin, cisplatin, or gemcitabine or for 5 months after the last dose of atezolizumabXx_NEWLINE_xXNon-Childbearing Potential: Male subjects and their partners must meet one of the following criteria to be considered of non-childbearing potential:Xx_NEWLINE_xXMen with partners of childbearing potential willing to use adequate contraceptive measures during the study and for 90 days after the last dose of study medication.Xx_NEWLINE_xXNegative serum pregnancy test within 72 hours before starting study treatment for women of childbearing potential. Women of childbearing potential and all men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of monalizumab administration and for up to 5 months after the last dose of monalizumab.Xx_NEWLINE_xX